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ABSTRACT 
 
THE ASSOCIATION BETWEEN MEDICATION ADHERENCE IN MENTAL 
ILLNESS AND SUBSTANCE USE DISORDER RELAPSE IN PATIENTS WITH 
DUAL DIAGNOSIS 
 
 
By 
Tyler Dunn 
May 2018 
 
Thesis supervised by Dr. Jordan Covvey 
 
Objectives: The aims of the study were to (1) identify personal, social, and clinical 
history for patients with substance use disorder (SUD) and mental illness, (2) measure 
agreeance between patient self-report versus facility record history for mental illness, 
substance abuse, and psychotropic medication, (3) investigate the specific role of 
medication adherence and barriers to use for psychotropic medications upon SUD 
relapse, and (4) assess follow-up changes in mental illness severity and medication 
adherence in dual diagnosis patients enrolled in a substance abuse rehabilitation program.  
Methods: The pilot study utilized a mixed methodology. Inclusion criteria included male 
patients at least 18 years of age who were newly admitted at a 90-day residential 
rehabilitation program with a self-reported diagnosis of SUD, and either major depressive 
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disorder (MDD), bipolar disorder, generalized anxiety disorder (GAD) or schizophrenia. 
Patients were evaluated within their first week of treatment and follow-up interviews 
were conducted at 1 and 2 months. Facility records were accessed to cross-reference 
patient reported data, using Cohen’s kappa coefficient to determine agreement. Patient 
demographic characteristics, substance abuse characteristics, health-related 
characteristics, and attitude towards medications stratified by adherence rates and relapse 
rates utilizing ANOVA and t-tests. Pearson’s correlation coefficient was utilized to 
analyze the relationship between medication adherence and SUD relapse. A multivariable 
logistic regression model was created to assess the impact of adherence on relapse 
frequency. Patient and clinical characteristics were stratified according to follow-up 
interviews completed utilizing ANOVA and t-tests. Lastly, changes in patients’ self-
reported adherence from interview to interview were analyzed using mean difference. 
SPSS Statistics (IBM Corp; Armonk, NY) was utilized for all analyses, with a two-tailed 
level of significance at 0.05. 
Results: The final sample consisted of 38 patients. The majority of patients were white 
(n=27, 71.1%), unemployed (n=32, 84.2%), and homeless (n=30, 78.9%). Heroin was the 
most common primary drug of use (n=19, 50%), followed by alcohol (n=12, 31.6%), and 
crack cocaine (n=4, 10.5%). The average length of substance use was 20.3 years. Half of 
the patients (n=19, 50%) had two or more mental illness diagnoses and the most common 
was the combination of MDD and GAD (n=9, 23.7%), followed by MDD alone (n=7, 
18.4%), and bipolar disorder (n=6, 15.8%). Significant agreeance was found between 
patient self-reported data to facility records for primary substance of use (κ=0.753, 
p<.001), mental illness diagnosis (κ=0.434, p<.001), number of mental illness 
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comorbidities (κ=0.257, p=0.008), and number of psychotropic medications prescribed 
(κ=0.094, p<.001). Patients self-reported less comorbid diagnoses and more previous 
treatment stays compared to facility records. Patients receiving income prior to admission 
had higher relapse rates (16.9 vs 8.1, p=0.02). Self-reported relapse rate was negatively 
correlated with the Morisky Medication Adherence Scale (MMAS-8) intentional score 
(r= -.360, p=.026), MMAS-8 total score was positively correlated with self-reported 
adherence rates (r=.618, p<.001), the MMAS-8 intentional score (r=.869, p<.001), and 
the MMAS-8 unintentional score (r=.863, p<.001). MMAS-8 intentional score was 
positively correlated with MMAS-8 unintentional score (r=.552, p<.001) and self-
reported adherence rate (r=.613, p<.001). Lastly, the MMAS-8 score was positively 
correlated with self-reported adherence rate (r=.481, p<.001). For the regression model, 
MMAS-8 total score was a significant predictor of relapse rate (stand. beta = -.443, CI= -
6.37-0.23, p=.048) but the linear combination of the measures included was not 
significantly related to self-reported relapse rate (F=2.25, adjusted R2 =.145, p=.073). A 
total of 12 patients (31.6%) fully completed the study, 15 patients (39.5%) only 
participated in the first follow-up, and 11 patients (28.9%) only participated in the 
primary interview. DAI-10 total scores were lower in patients who only completed the 
primary interview vs. patients who completed the entire study (4.0 vs 7.0, p=.044). There 
was a significant increase in adherence at the first (mean difference=5.7, p<.001) and 
second (mean difference=6.5, p<.001) follow-ups compared to the primary interview. 
Conclusions: The study provided valuable insight into the relationship between 
psychotropic medication adherence and SUD relapse in patients with dual diagnosis 
which can be used by healthcare professionals and drug abuse rehabilitation programs.  
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CHAPTER 1 – INTRODUCTION  
I. Mental Illness 
a. Definition, burden, and impact 
Mental illness refers to a wide range of mental health conditions characterized by abnormal 
thoughts, perceptions, emotions, and behaviors that result in suffering or poor ability to function 
in life.1 The Diagnostic and Statistical Manual, 5th Edition (DSM-5) defines mental illness as “a 
syndrome characterized by clinically significant disturbance in an individual’s cognition, 
emotion regulation, or behavior that reflects a dysfunction in the psychological, biological, or 
developmental processes underlying mental functioning.”2 A serious mental illness (SMI) is 
defined as any mental, behavioral, or emotional disorder that substantially interferes with one or 
more major life activities.3 
 
Mental illness has a substantial impact on the population at-large. The World Health 
Organization (WHO) World Mental Health (WMH) Survey Initiative is a project that aims to 
obtain and assess accurate data about the worldwide prevalence of mental, behavioral, and 
substance disorders in 28 counties across 154,000 individuals. The WHM Survey Initiative’s 
most recent data from 2009 found the inter-quartile range (25th–75th percentiles across countries) 
of mental illness prevalence in the participating countries to be between 18.1% and 36.1%. The 
worldwide prevalence of SMI was estimated between 4% and 6.8% in half of the countries 
surveyed, between 2.3% and 3.6% in one-quarter of the countries, and between 0.8% and 1.9% 
in rest of the countries. A significantly higher 12-month prevalence of mental illness was found 
in the United States (US; 27.0%), Ukraine (21.4%), Colombia (21.0%), New Zealand (20.7%), 
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and France (18.9%) while Japan (7.4%), China (7.1%), and Nigeria (6.0%) had a significantly 
lower prevalence.4 
 
The National Survey on Drug Use and Health (NSDUH) is an annual survey of the US 
population with the purpose of collecting information and identifying trends of behavioral health 
in citizens 12 years and older. In 2016, NSDUH identified 44.7 million adults over the age of 18 
as having a mental illness, accounting for 18.3% of the total population. NSDUH also found that 
10.4 million adults had a SMI within the past year (4.2%). The number of adults with mental 
illness in the population remained stable from 2008 to 2016. Mental illness had a higher 
prevalence among adults 26 to 49 years old (21.1%) and 18 to 25 years old (22.1%) compared to 
adults aged 50 or older (14.5%).5 
 
Mental illness results in a high economic burden due to its debilitating effect on the patient’s 
capacity to function. Therefore, unlike other common medical conditions, mental illness has 
higher indirect costs than direct costs. Notable indirect costs include reduced labor force 
participation, caregiver burden, public disability supplementation, and costs associated with 
imprisonment and homelessness. The annual loss of earnings alone is estimated to be $193.2 
billion per year.6 When combining indirect and direct costs, mental illness is estimated to cost 
the US approximately $317 billion per year, or more than $1,000 per capita.7 
 
Mental illness has an impact on patient’s functioning ability due to its effect on basic activities of 
daily living, interpersonal relationships, and the ability to function in the workplace. According 
to the WHO, mental and behavioral disorders account for 13.6% of the total US disability-
  3 
adjusted life years (DALYs), ranked third in DALYs in the US, only behind cardiovascular and 
circulatory disorders and neoplasms.8 In study of global burden of diseases by Gore et al., 
researchers concluded that 45% of all DALYs of youth between 10 and 24 years old were 
attributed to psychiatric disorders.9 It is estimated that there are currently 165,000 homeless 
people in the US who suffer from a serious mental illness.10  The debilitating nature of the 
disease may play a role in this high prevalence rate. The high level of DALYs and rate of 
homelessness in mentally ill patients shows that not only is mental illness highly prevalent, but 
also has a significant impact on the functioning ability of those who are affected by it.  
 
b. Diagnosis  
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) is the 
classification and diagnostic tool used by healthcare professionals worldwide to diagnose a 
clinical mental disorder. The goal of the DSM-5 is to ensure that clinicians can accurately and 
consistently diagnose patients with mental illness. The DSM is reviewed and revised periodically 
by the American Psychiatric Association (APA) to adjust to new advances and discoveries in 
mental health research. The current 5th edition was published in 2013.11 The DSM-5 is often used 
to make decisions regarding treatment plans and payments, therefore it provides a uniform tool 
for healthcare professionals to use to avoid variability that may have a negative impact on the 
patient.  
 
In addition to DSM-5, other mental health assessment tools are utilized during the mental illness 
diagnosis process in order to enable an earlier identification of the disease and prevent a 
misdiagnosis, therefore, leading to a more effective treatment plan. They also provide medical 
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professionals with a common objective metric that can assure a consistency in diagnoses. 
Although a medical professional is needed to make a clinical diagnosis, these tools also assist 
patients with a quick, easy, and low-cost way to determine if they are experiencing mental illness 
symptoms. Mental health assessments tools can be used as general mental health screening tools 
or can be disorder specific severity measures.12 
 
c. Etiology and risk factors 
The exact causation of mental illness is complex and fluctuates from condition to condition. Risk 
factors for the development of mental illnesses include genetics, environmental factors, social 
influences, and illicit drug use. 
 
Multiple studies have indicated that genetic factors play a role in the development of mental 
illness. Sellers et al. conducted a longitudinal study to assess if a mother's recurrent depression 
predicted new-onset psychopathology in their children.13 The study found that the number of co-
occurring mental illnesses in the mother (0, 1, or 2+) predicted new-onset offspring disorders 
(OR = 1.80, 95% CI 1.17–2.77, p = 0.007), therefore concluding an increased risk of future onset 
psychiatric disorders in offspring from pre-existing mental illness.13 Another study conducted by 
Singh et al. set out to assess the link between genetics and mental illness by administering 
structured interviews among twins, their spouses, and their children; this demonstrated an 
association between parental and offspring depression (HR 1.52, CI 1.20–3.93, p ≤ .05). After 
controlling for measured covariates such as sex, divorce rate, and education level, this 
association was found to be due to shared genetic liability.14 
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Studies have also shown mental illness to be linked to environmental factors surrounding 
pregnancy and birth. A population study done in the UK by Dorrington et al. found an 
association between psychosis in offspring and the mother experiencing stressful life events 
while pregnant (OR = 1.10, CI 1.02–1.18, p ≤.05).15 A wide variety of other prenatal 
environmental conditions and stressors are correlated with mental illness such as fetal hypoxia,16 
maternal infections,17 maternal exposure to influenza18 and maternal malnutrition.19 
 
Social influences and external factors have been shown to have an effect on the development and 
severity of mental illness in those who are genetically and biologically vulnerable to mental 
illness. Recent studies have linked the development of mental illness to sexual abuse,20 physical 
abuse,21 emotional abuse,22 domestic violence23 and bullying.24 Childhood trauma such as poor 
parenting and neglect has been found to be a risk factor for both depression and anxiety.25,26 
 
Substance abuse, especially long-term use, can increase the risk of mental illness. Heavy alcohol 
use or dependence has been linked to major depressive disorder.27 Heavy marijuana use, 
especially at a young age, has been linked to depression and anxiety.28 Marijuana users are at 
double the risk of having a psychotic episode or developing long-term schizophrenia, and 
children who use marijuana at before the age of 20 have a higher risk of developing bipolar 
disorder.29 The use of drugs such as cocaine and amphetamines have been found to put an 
individual at a higher risk of developing schizophrenia.30 
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d. Treatment modalities 
There are different methods to treat mental illness, with the most effective treatment plans being 
the ones tailored to patient- and condition-specific needs. A variety of different healthcare 
professionals can provide mental health treatment such as primary care physicians, psychiatrists, 
psychiatric health nurse practitioners, clinical psychologists, psychiatric pharmacists, and social 
workers. Facilities that provide mental illness treatments include hospitals, clinics, and a variety 
of different community mental health services. Mental illness is typically treated through a 
combination of psychotropic medications and psychotherapies but other complementary 
treatment modalities can be added to a patient’s care plan.31 
 
Psychotropic medications play a key role in the treatment of mental illness. The five main 
psychotropic categories are antidepressants for depression, anti-anxiety or anxiolytics for anxiety 
disorders, antipsychotics for psychosis disorders such as posttraumatic stress disorder (PTSD), 
obsessive-compulsive disorder (OCD) and schizophrenia, mood stabilizers for bipolar disorder, 
and stimulants for attention deficit disorders (ADD).32 If taken as prescribed, psychotropic 
medications have been shown to be efficacious in treating mental illness. In a meta-analytic 
study of the short-term efficacy of antidepressants versus a placebo, Storosum et al. found 
significant decrease in symptom severity using the Hamilton Depression Rating Scale.33 Another 
meta-analysis conducted by Barbui et al. concluded that paroxetine, a selective serotonin 
reuptake inhibitor (SSRI), was more effective than placebo in increasing the amount of patients 
who experienced improvement in at least half of their symptoms (RR 0.83, 99% CI 0.77–0.90).34 
The mood stabilizer lithium has been found to be highly effective in treating bipolar disorder, 
reducing the frequency of symptom relapse by 50% (Hedges- Olkin effect size =0.68, CI =0.60-
  7 
0.76).35 While a majority of studies show psychotropic medications to be efficacious, their 
outcomes may vary due to factors such as disease severity, duration of disease, and 
comorbidities.   
 
Psychotherapy refers to a variety of treatment techniques that aim to help a patient overcome the 
negative effects of the mental illness they are struggling with. Through psychotherapy, a 
psychologist helps the patient understand their condition and develop healthier and more 
effective habits of coping with the condition. There are different types of psychotherapies 
including cognitive behavioral therapy, interpersonal therapy, family therapy, and condition 
specific therapies.36 Of the types of psychotherapies, cognitive behavioral therapy (CBT) is the 
most commonly used in the treatment of mental illness. CBT is short-term and talk-centered 
psychotherapy that aims to improve the patient’s underlying thoughts and actions that result in 
negative experiences. CBT helps improve the patient’s cognitive processes by changing their 
current thoughts, personal images, beliefs, and attitudes in regard to their emotional problems. 
CBT is especially effective in the mental illness population due to its focus on teaching patients 
coping skills and how to apply these skills to their current situation. Those with mental illness 
experience a decrease in functioning ability and have a higher need for the development of 
coping skills. For example, a patient with major depressive disorder (MDD) may learn how to 
pay more attention to their negative thoughts and approach them with a more realistic analysis 
therefore preventing the patients from experiencing a decrease in mood. CBT is also effective for 
mental illness treatment due to its focus on improving one’s self-beliefs. For example, mental 
illness patients may feel inferior, mentally flawed, or stigmatized by others. CBT helps patients 
dispel those beliefs and accept oneself for who they are.37 
  8 
 
Along with psychotherapy and medications, a patient with mental illness may also consider other 
treatment options to supplement their care plans. Lifestyle changes such as dietary adjustments, 
gainful employment, stress reduction, and peer support have been showed to help decrease 
symptoms in certain conditions such as depression and anxiety.38 Non-clinical interventions have 
also been shown to be effective treatment options. A study by Talwar et al. found that a 
combination of music therapy plus standard care can reduce symptom severity in patients with 
schizophrenia when compared to standard care alone.39 Yoga has also been found to improve the 
symptoms of mental disorders. In a meta-analysis conducted by Klatte et al., body-oriented yoga 
was found to lower a patient’s mental illness symptom severity (Hedges' g = 0.91; 95% 
confidence interval 0.55-1.28).40 In rare cases, psychosurgery treatments can be utilized such as 
transcranial magnetic stimulation, vagal nerve stimulation, stem cell therapy, deep brain 
stimulation, and electroconvulsive therapy.41,42 
 
e. Specific mental illness conditions 
i. Major depressive disorder 
Major depressive disorder (MDD), commonly referred to as clinical depression, is the most 
common mental illness in the US. MDD negatively affects one’s emotions, thoughts, and actions 
causing the patient to be in a state of sadness and disinterest. Characteristics of MDD include 
depressed mood, loss of interest in activities, changes in appetite, trouble sleeping, fatigue, 
restlessness, decreased concentration, and thoughts of suicide.43 In the Global Burden of Disease 
Study of 2013, approximately 253 million people or 3.6% of the global population were found to 
be affected by MDD.44 In 2015, the National Institute of Mental Health (NIMH) estimated that 
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16.1 million or 6.7% of the US population aged 19 or older suffer from MDD. MDD accounts 
for 3.7% of all US DALYs, the highest among mental disorders.45 The annual cost of illness is 
approximately $210.5 billion with 45-47% accounting for direct costs, 48-50% accounting for 
loss of productivity, and 5% to suicide-related costs.46 
 
A diagnosis of MDD requires a patient to have a depressed mood or loss of interest in nearly all 
normal activities for at least two weeks duration. The patient must also have at least three of the 
following symptoms: insomnia or hypersomnia, feelings of worthlessness or excessive guilt, 
fatigue or loss of energy, diminished ability to think or concentrate, substantial change in 
appetite or weight, psychomotor agitation, and recurrent thoughts of death or suicide.47 Not all 
patients with MDD experience the same symptoms. The severity, duration, and frequency of 
MDD symptoms vary according to the individual patient and also depend on the stage of the 
illness.48 The Patient Health Questionnaire (PHQ-9) is the most commonly used MDD 
assessment tool, which consists of ten questions assessing the frequency and severity of the 
patient’s MDD symptoms.12 
 
Treatment for MDD utilizes a combination of medication and psychotherapy. Medication options 
for patients with MDD include selective serotonin reuptake inhibitors (SSRIs), serotonin 
norepinephrine reuptake inhibitors (SNRIs), bupropion tricyclic antidepressants (TCAs), and 
monoamine oxidase inhibitors (MAOIs). Medication choice is based on patient preference, 
history of prior medication, safety, tolerability, side effects, and cost. Generally, MAOIs are only 
prescribed to patients who have not responded to previous medications.49 TCAs and MAOIs are 
first generation medications that enhance the body’s serotonin and norepinephrine production 
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mechanism but also block histaminic and cholinergic receptors sites therefore resulting in 
unwanted medication side effects. SSRIs and SNRIs are new generation antidepressants that 
target specific brain receptor sites therefore resulting in less unwanted side effects.50 Lifestyle 
changes such as physical activity and diet change are also recommended to help counteract the 
symptoms of MDD.51 
 
ii. Generalized anxiety disorder 
Anxiety disorders are states of abnormal and excessive nervousness, anxiousness, and fear. 
Generalized anxiety disorder (GAD) is a chronic mental illness in which a patient is in a constant 
state of worriedness that interferes with his or her daily activities. GAD can also cause physical 
symptoms such as restlessness, fatigue, lack of concentration, muscle tension, and problems 
sleeping. Due to the severe symptoms of GAD, patients usually struggle with holding a job or 
completing everyday activities.52 Kessler et al. estimated that the lifetime prevalence of GAD in 
the US at 4.3% and the twelve-month prevalence at 2.0%.53 In general, GAD is more likely to 
affect females than males.54 GAD also has a high economic burden on patients, with a mean 
annual direct medical cost for a patient with GAD estimated at $6,475.55 
 
According to the DSM-5, a diagnosis of GAD requires a patient to have excessive anxiety on the 
majority of the days for at least six months, difficulty controlling their worrying, and three or 
more of the following symptoms; restlessness, fatigue, difficulty concentrating, irritability, 
muscle tension, and sleep disturbance.56 A thorough mental health evaluation is essential to a 
GAD diagnosis due to the high risk of a misdiagnosis. Anxiety can be brought on by other 
physical health conditions such as hyperthyroidism or hypoglycemia. Certain medications may 
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result in anxiety as a side-effect. Other untreated mental illnesses such as OCD and MDD can 
also increase a patient’s anxiety level.57 The Generalized Anxiety Disorder – 7 item scale (GAD-
7) is the most commonly used screening tool that helps indicate whether or not a patient requires 
a complete clinical assessment for GAD. The GAD-7 assess the frequency of common GAD 
symptoms over the past 2 weeks, ranging from symptoms are not present at all to symptoms are 
present nearly every day.12  
 
Medications are used to relieve the symptoms of GAD but they do not cure the disorder itself. 
Anti-anxiety medications are used to reduce the symptoms of GAD including excessive anxiety, 
panic attacks, and extreme fear and worry.57 Benzodiazepines are the first-line anti-anxiety 
medications for GAD but should only be used short-term due to their high potential of 
dependence and abuse.32 Benzodiazepines treat GAD by inducing relaxation in the patient and 
reducing muscular tension. Beta-blockers can be prescribed to help relieve the physical 
symptoms of GAD such as rapid heartbeat, shaking, and trembling. Antidepressants have also 
been shown to be effective for treating anxiety.57 Stress management, meditation, and support 
groups have also been shown to help alleviate the symptoms of GAD.52 
 
iii. Bipolar disorder 
Bipolar disorder, sometimes referred to as manic-depressive disorder, is characterized by unusual 
and extreme shifts in mood, energy, activity levels, and ability to function in everyday activities. 
Patients with bipolar disorder experience shifts in emotional episodes ranging from manic highs 
to depressive lows. The side-effects of a manic episode include feeling euphoric, high energy, 
trouble sleeping, and exhibiting risky behavior such as spending money or engaging in unsafe 
  12 
sexual practices. The side-effects of depressive episodes include extreme sadness, low energy, 
over sleeping, anxiety, trouble concentrating, and thoughts of suicide.58 A patient can be 
diagnosed as either bipolar I or bipolar II. While both of these diagnoses include similar 
depressive episodes, bipolar I patients experience much more severe mania episodes compared to 
bipolar II patients. Bipolar II patients experience hypomania, which is a less severe form of 
mania that would be considered atypical but not abnormal. Bipolar I patients exhibit manic 
behaviors which are more extreme and abnormal.59 In the US adult population, the lifetime 
prevalence of bipolar disorder is estimated to be 3.9% and the annual prevalence is 2.6%. Bipolar 
disorder is more likely to affect younger patients between 18-29 years old and a lower 
prevalence is seen in the older population above the age of 60. The average age-of-onset is 25 
years old.60 A systematic review of cost of illness studies for bipolar disorder conducted by 
Kleine-Budde et al. found that the cost per capita in the US ranged from $8,000 to $14,000 per 
year in direct healthcare costs and $2,000 to $11,000 in indirect costs.61 
 
Bipolar disorder is usually diagnosed in adolescence or early adulthood but can occur at any 
age.62 Diagnosing a patient with bipolar disorder is difficult due to the various other mental 
illnesses that share similar symptoms such as MDD, substance-induced mood disorder, ADHD, 
and conduct disorder.63 Another reason diagnosing is difficult is because a patient is more likely 
to seek treatment during a depressive state compared to a maniac state therefore possibly 
receiving an inaccurate MDD diagnosis.58 The most common screening tool for bipolar disorder 
is the Mood Disorder Questionnaire (MDQ), which consists of 13 questions evaluating the 
presence of common symptoms.12 Other measures and rating scales used to evaluate bipolar 
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disorder include the General Behavior Inventory (GBI), the Bipolar Spectrum Diagnostic Scale 
(BSDS), and the Hypomania Checklist (HCL-32).64  
 
While there is no cure for bipolar disorder, medications are used to control the manic and 
depressive episodes. Mood stabilizers help the patient control mood swings by decreasing 
abnormal brain activity. Antipsychotics are typically prescribed to help manage the psychosis 
caused by the manic phases such as delusions or hallucinations. Antidepressants are used to treat 
the depressive phase of bipolar disorder in the same way they are used to treat MDD. A patient 
taking medication for bipolar disorder should be heavily monitored by their doctor or pharmacist. 
When a patient is experiencing a manic phase, they may believe they do not need to take the 
medication and sudden stoppage of bipolar medication leads to worsening of symptoms and in 
some cases to potentially fatal withdrawal side-effects.32 
 
iv. Schizophrenia 
Schizophrenia is defined as a long-term mental illness characterized by a breakdown of thoughts, 
emotions, and behaviors that cause a patient to have a distorted perception of reality, leading to 
inappropriate actions and a withdrawal from everyday life. Although schizophrenia is less 
prevalent than other mental disorders, it is associated with more severe and debilitating 
symptoms. There are three different categories of symptoms that a patient with schizophrenia 
experiences: positive symptoms, negative symptoms, and cognitive symptoms. Positive 
symptoms are psychiatric behaviors that are not present in those without schizophrenia. These 
symptoms include visual or audible hallucinations, delusions, extreme paranoia, and unusual or 
dysfunctional thoughts. Negative symptoms are deficits in normal emotional or physical 
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processes such as extreme reduction in emotional expression, reduced feeling of pleasure, lack of 
speech, lack of motivation, and lack of desire to engage in social relationships. Cognitive 
symptoms are deficits impacting the cognitive functioning of the patient. These symptoms 
include a poor ability to understand information or make decisions, trouble paying attention, and 
poor memory.65 
 
There are currently more than 2.6 million people in the US that suffer from schizophrenia which 
reflects 1.1% of the population.65 Of those 2.6 million patients, it is estimated that 40% are 
untreated.66 There are significantly more males affected by schizophrenia than females.67 
Schizophrenia has a high economic burden due to the disease’s high disability; Chong et al. 
estimated the total economic burden for the US at $102 million, with indirect costs responsible 
for 50-85% of the total cost of illness.68 
 
Schizophrenia is usually diagnosed when the patient is between 16 and 30 years old but in some 
rare cases, children have also been diagnosed with the disease.65 According to the DSM-5, a 
diagnosis of schizophrenia requires a patient to have three of the five following symptoms: 
delusions, hallucinations, disorganized speech, disorganized or cationic behavior, and negative 
symptoms.69 The Brief Psychiatric Rating Scale (BPRS) is a tool used to assess the severity of 18 
symptoms that are commonly associated with schizophrenia such as anxiety, grandiosity, 
hostility, hallucinations, and emotional withdraw. The BPRS can be used to evaluate if a patient 
is schizophrenic or to assess the efficacy of schizophrenia treatment.70 
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The causation of schizophrenia is relatively unknown; therefore, the treatment of the disease 
focuses on controlling symptoms. Schizophrenia is treated through a combination of 
antipsychotics and psychotherapy. Coordinated specialty care (CSC) is a vital part of 
schizophrenia treatment due to the severity of the disease. CSC is the integration of typical 
medication and psychotherapy treatment with other supplemental treatments such as case 
management, family involvement, supported education, and employment services in order to 
reduce symptoms and improve the patient’s quality of life.65 
 
II. Substance Use Disorder 
a. Definition, burden and impact 
Clinicians classify the level to which patients use illicit drugs or alcohol into three categories; 
substance use, substance abuse, and substance use disorder (SUD). The purpose of using these 
terms is to help professionals determine the severity of the impact that substance use has on the 
user’s ability to function. Substance use refers to the low frequency and irregular use of illicit 
drugs. Typically, a person’s life is not significantly impacted by substance use until the pattern 
evolves into substance abuse.71 
 
Substance abuse refers to the repeated use of psychoactive substances such as alcohol and illicit 
drugs, despite known harmful consequences, one or more times in a twelve-month period that 
leads to significant impairment.72,73 The results of substance abuse may include struggling with 
home, work, and school obligations, substance-related legal problems, and interpersonal 
problems.73 In 2014, 27 million people in the US were identified as illicit drug users, accounting 
for 10% of the US population.3  
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Substance use disorder (SUD), commonly referred to as drug addiction, is a distinct medical 
condition that falls under the mental illness umbrella, but will be discussed as a separate entity in 
order to establish a clear distinction. SUD is defined by the DSM-5 as “the recurrent use of 
alcohol and/or drugs causing clinically and functionally significant impairment, such as health 
problems, disability, and failure to meet major responsibilities at work, school, or home.”74 
Substance abuse progresses into SUD when the user develops a tolerance to the drug, uses for an 
extended period of time, experiences difficulty stopping or controlling use, and experiences 
withdrawal symptoms when not using.73 In 2014, 21.5 million people in the US had a SUD in the 
past year, 8.1% of the total population. Of those 21.5 million, 1.3 million were between the ages 
of 12 to 17, 5.7 million were between 18 to 25 years old, and 14.5 million were 26 year or older.3 
 
Substance abuse and SUD result in a large economic burden to the US due to lost productivity, 
direct healthcare costs, and crime. It is estimated that the annual cost of substance use is more 
than $600 billion.75 According to the National Drug Threat Assessment created by the US 
Department of Justice’s National Drug Intelligence Center, substance use results in more than 
$120 billion per year in lost productivity. This includes reduced labor participation ($49 billion), 
loss of productivity due to incarceration ($48 billion), and drug-related deaths ($4 billion).76 An 
estimated 67% of current drug users over the age of 18 are employed either part-time or full-
time. Another large societal cost due to drug use are criminal justice costs such as criminal 
investigations, prosecutions, incarcerations, and victim costs, estimated at $61 billion annually.77  
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Substance abuse often leads to other medical problems therefore resulting in more complications 
and a lower quality of life for the patient. The injection of drugs such as heroin, cocaine, and 
methamphetamine play a major role in the spread of infection diseases including HIV/AIDS, 
hepatitis B, and hepatitis C.78 Injection drug use accounts for roughly 12% of all new AIDS 
cases.79 Excessively consuming alcohol damages many vital organs including the brain. Cocaine 
and other stimulant use can lead to complications of the heart, respiratory system, nervous 
system, and the digestive system. Due to the intoxicating effect of drug use, many users engage 
in frequent and unsafe sexual practices, therefore increasing their likelihood of contracting a 
sexually transmitted disease.78 
 
b. Diagnosis 
According to the DSM-5, a clinical diagnosis of SUD requires a patient to exhibit a minimum of 
two of the following symptoms: 1) Overconsumption or consuming more than originally 
planned, 2) failure to control one’s use of the substance, 3) spending extended amounts of time 
using, 4) failing to fulfill major obligations such as school, work, or home duties, 5) experiencing 
cravings for the substance, 6) continued use despite physical and mental health problems, 7) 
continued use despite negative effects on social life, 8) using the substance in a dangerous way 
such as drinking and driving, 9) withdrawing from regular activities due to use of substance, 10) 
building a tolerance to the substance, and 11) experiencing withdraw symptoms.80 A diagnosis of 
SUD then can be categorized according to severity level, ranging from mild to severe. A 
diagnosis of mild SUD requires the patient to display two or three of the listed symptoms, 
moderate requires four to five symptoms, and severe requires six or more symptoms.81 
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c. Etiology and risk factors 
While it is still uncertain what exactly causes an individual to be prone to substance abuse, 
several studies have identified predicting factors. A majority of risk factors for substance abuse 
are thought to occur during the user's childhood or adolescence. In a study conducted by 
Kilpatrick et al., 4,000 adolescents were interviewed in order to determine risk factors for current 
substance abuse. The researchers concluded that children and adolescences who experienced or 
witnessed physical, verbal, or sexual abuse were more likely to develop a drug use habit later in 
life. The researchers also concluded that children who had a family member with SUD were 
more likely to use drugs, suggesting either an environmental or genetic link.82 Another study 
conducted by White et al. found that childhood neglect and abuse play a significant role in the 
development of substance abuse.83 In a study of 1,760 young adults, Barrett et al. reported that a 
child who was raised in a single parent household is more likely to use drugs in their lifetime 
when compared to children raised in a two-parent household.84 In regards to alcohol, a study 
conducted by Ohannessian et al. found that children with parents who suffer from alcoholism 
have a higher predisposition to developing alcoholism later in life when compared to children of 
non-alcoholic parents.85 Other factors that increase substance use risk include peer substance use, 
drug availability, early aggressive behavior, and low socioeconomic status.86 
 
d. Treatment modalities 
As with most mental illnesses, SUD is treated through a patient-tailored combination of 
psychological therapy and medication therapy. Initial treatment of acute withdrawal often 
includes medical detoxification, which is a set of medical interventions with the purpose of 
managing acute intoxication and withdraw symptoms. Through detoxification, harmful toxins in 
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the bloodstream are eliminated though dieting, drug abstinence, withdrawal management, and 
medications. The most commonly used medications for detoxification are anxiolytics and 
methadone.87 Detoxification is not required for certain drugs, including cocaine, 
methamphetamine, and marijuana, because the withdraw symptoms are not as severe compared 
to other drugs. Certain drugs absolutely require detoxification because the withdrawal symptoms 
are so severe that they may be fatal if not properly treated. These drugs include alcohol, heroin 
and opioid prescription drugs.88 
 
After detoxification, it is recommended that the patient seeks help from a professional 
psychologist to make a treatment plan tailored to their needs with a focus on health, living 
situation, the individual’s purpose for quitting, and community support.89 There is currently a 
wide range of treatment options available including individual counseling and group counseling, 
inpatient and residential treatment, outpatient treatment, hospital programs, recovery support 
services, 12-step programs such as Alcoholics Anonymous (AA) or Narcotics Anonymous (NA), 
and peer support groups. Cognitive-behavioral therapy has been shown to improve outcomes in 
SUD by helping the user recognize factors that lead to their negative behavioral patterns such as 
stressors, negative situations, and actions that lead to substance use.90 Motivational interviewing 
has also been shown to be effective in implementing behavioral change in those with SUD.91 
Along with psychotherapy, the addition of social and family support has been shown to be 
critical to helping the patient adhere to their recovery plan.90 
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i. Relapse 
SUD is a chronic disease and the recovery stage of the disease lasts for the entire duration of the 
patient’s life. When a patient with SUD quits using for an extended period of time and then 
resumes using again, it is referred to as a relapse. Similar to most chronic diseases, those with 
SUD often experience periods of remission and relapse. Relapses are commonly caused by 
triggers, or external circumstances that cause the patient emotional or psychiatric distress such as 
anxiety, panic, stress, depression or discouragement.92 Triggers can be classified into three 
groups: environmental, re-exposure, and stress. Environmental triggers are circumstances that 
the patient once associated with drug use such as social events or friends. Re-exposure triggers 
are events in which the patient is in the presence of drug use therefore leading the patient back to 
their previous drug seeking behavior. Stress triggers are events that cause intense emotional 
states such as anger, fear, anxiety, and sadness that lead the patient to returning back to use.93 
Experts suggest patients at risk of relapse identify triggers and develop an action plan of what 
steps to take when they find themselves in trigger situations.92 
 
e. Specific substance use disorders 
i. Alcohol 
Of the 21.5 million people with a SUD last year, 17 million (6.4% of the total US population) 
had an alcohol use disorder. Alcohol use is broken down into three different categories: current 
alcohol use, binge alcohol use, and heavy alcohol use. These are the criteria used by the 
Substance Abuse and Mental Health Services Administration (SAHMSA) to categorize the 
levels of alcohol use and do not equate to a diagnosis of SUD. Current alcohol use is defined as a 
person having any alcoholic drink within the last 30 days. Binge alcohol use is defined as a 
  21 
person having five or more drinks or drinking to a point of intoxication at least once in the last 
30 days. Heavy alcohol use is defined as drinking five or more drinks or drinking to a point of 
intoxication five or more times in the past 30 days. In 2014, 139.7 million people were current 
alcohol users, 60.9 million people were binge alcohol users, and 16.3 million were heavy alcohol 
users.3 In 2011, Bouchery et al. calculated the economic cost of alcohol consumption in the US 
including healthcare costs, productivity losses, and other miscellaneous costs such as property 
damage; the total estimated economic costs of excessive drinking were $223.5 billion, with 
72.2% in lost productivity, 11% in healthcare costs, 9.4% in criminal justice costs, and 7.5% in 
other miscellaneous costs. This cost can be broken down to approximately $746 per person or 
$1.90 per alcoholic drink consumed per year.94 
 
ii. Illicit drugs 
Of the 21.5 million people with a SUD last year, 7.1 million had an illicit drug use disorder 
which represents 2.7% of the total population. An estimated 867,000 of those with illicit drug use 
disorder were between 12 and 17 years old, 2.3 million were between 18 and 25 years old, and 
3.9 million were 26 years and older.64 The most common illicit drug use disorders in the US are 
cannabis use disorder, stimulant use disorder, and opioid use disorder.74 While there are many 
other SUDs prevalent in the population, the following three SUDs will be focused on because 
they are the most common in the US.  
 
1. Marijuana 
Marijuana is currently the most used illicit drug in the US. In 2014, 22.2 million people reported 
using marijuana within the last month, and 4.2 million met the criteria for a SUD based on their 
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marijuana use alone.95 The short-term effects of marijuana include distorted perception, 
difficulty thinking and problem solving, and reduced motor skill coordination. The symptoms of 
cannabis use disorder include tolerance to the drug, drug cravings, difficulty sleeping, anxiety, 
anger, and depression. Long-term use has been proven to cause respiratory infection, impaired 
memory, and cancer. Early age marijuana use has also been linked to mental illness and poor 
cognitive functioning.74 
 
2. Stimulants 
Stimulants are drugs that increase alertness, attention, and energy, and have a high potential for 
abuse due to the euphoric state the user experiences. The term stimulants can refer to prescription 
medications such as methylphenidate or illicit drugs such as amphetamines, methamphetamines, 
and cocaine. In 2014, 1.6 million people were current nonmedical users of non-cocaine 
stimulants, of which 569,000 were current users of methamphetamine. It is estimated that 1.5 
million people are current cocaine users of which 913,000 have a current cocaine use disorder.3 
Symptoms of stimulant use include drug cravings, loss of control of use, tolerance, high blood 
pressure, increased heart rate and respiration. The withdraw symptoms of stimulants include 
fatigue, trouble sleeping, increased appetite, and irregular or spastic movements.74 
 
3. Opioids 
Opioid use and abuse is currently a nationwide problem that is severely impacting the health, 
social, and economic state of the US. Opioid abuse can refer to the use of prescribed painkillers 
such as hydrocodone, oxycodone, morphine, and codeine in a manner that does not coincide with 
a physician’s directions. Prescription opioids are prescribed to reduce a patient’s pain but may be 
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taken recreationally due to the intense high and euphoria they induce. Opioid abuse can also 
occur when the patient takes the medication for pain but not according to physician 
recommendations. In 2014, it was estimated that 4.3 million Americans used a prescription 
opioid for nonmedical purpose and 1.9 million had an opioid use disorder due to prescription 
opioids.96 In 2014, there were nearly 18,000 reported deaths due to prescription opioids, a 3.4-
fold increase from 2001.97 The most common drugs responsible for overdoses are methadone, 
oxycodone, and hydrocodone.98 Experts contribute the severity of the problem to the increase in 
number of opioids prescribed by physicians, which has increased from 76 million in 1991 to 207 
million in 2013. The US is the largest consumer of opioid drugs, prescribing nearly 100% of the 
world total of hydrocodone and 81% of the world total of oxycodone.99 Over the past few 
decades, the U.S. Food and Drug Administration (FDA) has made a priority of solving the 
problems of opioid misuse, abuse, and addiction by targeting and improving drug development, 
drug packaging and labeling, prescriber and patient education, and addiction treatment efforts.100 
 
In addition to prescription drugs, opioid abuse can also refer to the use of illicit substances such 
as heroin, a powerful and lethal opiate synthesized from morphine. Many heroin users misuse 
prescription opioids and then progress to using heroin due to the substantial cost difference. The 
side effects of heroin use include an intense euphoria, drowsiness, respiratory depression, and 
nausea. Symptoms of a heroin overdose include trouble breathing, blue lips and fingernails, 
uncontrollable sweating, convulsions, coma, and death.96 In 2014, there were 435,000 people in 
the US who have used heroin in the past month and 586,000 had a heroin use disorder.3 It is 
estimated that 4.8 million people have used heroin in their lifetime.96 There were more than 
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10,000 deaths involving heroin in the US in 2014, which accounts for a 6-fold increase from 
2001.97 
 
III. Dual diagnosis 
a. Definition, burden and impact 
Dual diagnosis is the co-occurrence of a mental illness and SUD. Patients with dual diagnosis 
exhibit more persistent, severe, chronic, and treatment-resistant symptoms when compared to 
patients with SUD or a mental illness alone. The presence of a dual diagnosis in a patient results 
in more severe negative health outcomes such as relapse of psychiatric illness, hospitalization, 
disruptive behavior, family stress, homelessness, legal problems, decreased functioning status, 
HIV infections, and low medication adherence.101 
 
In 2014, it was estimated that 7.9 million adults had a dual diagnosis, representing 39.1% of the 
total SUD population, 18.2% of persons with mental illness, and 3.3% of the total US population. 
It is estimated that there are currently 2.3 million adults (1.0% of the US population) with a 
serious mental illness and SUD. Of the 7.9 million dually diagnosed patients, 36.0% were 
between the aged of 18 and 25 years, 42.7% were between 26 and 49 years, and 35.6% were 50 
or older.3  
 
b. Diagnosis 
Accurately diagnosing a patient with a dual diagnosis has been proven to be difficult for 
physicians. Dual diagnosis is currently not a distinct diagnosis in the DSM-5, therefore there is 
no standardized diagnosis criteria that can assist physicians to make a proper diagnosis.102 
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Diagnosis is further complicated with symptoms of substance abuse and acute withdrawal being 
similar to mental illness symptoms. Withdrawal from alcohol in most cases causes patients to 
exhibit symptoms of depression, and psychedelic drugs cause patients to display symptoms 
similar to schizophrenia and psychosis. Withdrawal from stimulants cause extreme anxiety in 
their users. For a patient to truly have a dual diagnosis, the mental illness must still be present in 
the absence of drug use or after acute withdrawal has taken place, or must have been present 
prior to establishment of the substance use disorder. Therefore comorbid SUD and mental illness 
has been problematic to accurately diagnose.103 
 
c. Etiology and theories of development 
Despite the high prevalence and severity of dual diagnosis, little is known as to why the co-
occurrence of these two diseases happens but there are some theories established by previous 
research. The highly debated causality theory states that heavy and long-term drug use leads to 
the development of mental illness. For example, a study conducted by Moore et al. concluded 
there was an increased risk of a psychotic event in those who have used cannabis compared to 
those who have not (adjusted OR =1.41, 95% CI 1.20–1.65, p=0.28). Moore et al. also found a 
dose-response effect, there was an increased risk of a psychotic event in those who used cannabis 
more frequently compared to those who used less frequently (adjusted OR=2.09, 1.54–2.84; 
p=0.11).104 Other studies have also shown that use of stimulants and hallucinogens can lead to 
long-term psychotic disorders such as schizophrenia or affective disorder.105 
 
Another theory to explain the high co-occurrence of these disorders is the self-medicating theory. 
Patients with mental illness may be in a state of constant discomfort in which the use of illicit 
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drugs helps alleviate. The presence of a mental illness may cause a patient to experience extreme 
emotional highs and lows, and the use of illicit drugs may result in temporary alleviation of these 
feelings or give the patient a perceived control over them.106 A patient receiving treatment for 
their mental illness may also use illicit drugs to regulate the side effects of psychotropic 
medications. For example, a frequent side effect of antipsychotic medications is sedation and 
lack of energy therefore patients may use stimulants such as amphetamines to counteract the 
sedation.107 There are currently multiple diagnostic studies that both support and reject the self-
medicating theory.106 
 
Another theory used to explain dual diagnosis is the alleviation of dysphoria theory. Dysphoria is 
a state of severe unease or dissatisfaction and is often experienced by those with depression and 
anxiety disorders. The theory states that patients with dysphoria are more likely to engage in 
illicit drug use to alleviate these feelings.107 In a study conducted on a cohort of inpatients with 
schizophrenia, it was found that patients with an alcohol-related diagnosis were more likely to 
cite alcohol use as a relief to their problems and worries.108 
 
The overlapping risk factors theory attempts to explain the co-occurrence of SUD and mental 
illness by crediting the high prevalence to the multiple overlapping risk factors for each disease. 
These factors include social isolation, low socioeconomic status, lack of adult role responsibility, 
lack of structured daily activity, and living in areas with high drug availability. There is also 
evidence that experiencing traumatic life events such as sexual or physical abuse can put a 
person at a higher risk for both mental illness and SUD.107  
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Lastly, the super sensitivity theory states that patients with mental illness also have biological 
and psychological vulnerabilities caused by genetic and environmental factors that make it more 
difficult to cope with negative or stressful life events. For example, a patient with major 
depressive disorder will not be able to deal with the loss of a love one as well as someone 
without a mental illness. Therefore, these individuals may not have the capability of sustaining 
moderate drug use and also be more likely to experience the negative consequences of illicit drug 
use such as addiction. The super sensitivity theory also provides an explanation to why patients 
with a mental illness often experience the negative consequences of drug use even while using 
relatively low levels of the substance.107 
 
d. Treatment modalities 
The dual diagnosis population often requires intense and patient-specific treatment due to the 
complexity and severity of their disease. There are many barriers to treatment for those with dual 
diagnosis and according to the 2015 National Survey on Drug Use and Health only 6.8% of those 
with a dual diagnosis received treatment for both their mental illness and SUD.109  While it is not 
completely clear why there is a lack of dual diagnosis specific treatment, some researchers 
conclude that it may be due to dual diagnosis patients being more difficult to work with, more 
likely to be noncompliant to treatment plans, less responsive to typical treatment, and more at 
risk of violence.110 A majority of previous research concludes that combining both mental illness 
and SUD treatment into a single care plan is the most effective way of treating dual diagnosis 
patients. In a literature review conducted by Drake et al., 26 controlled studies of dual diagnosis 
psychosocial therapy were observed and the most effective treatments were the mental illness 
and SUD integrated interventions that focused on individualized personal factors.111 
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IV. Medication adherence  
a. Definition, burden and impact 
The WHO defines adherence as "the extent to which a person’s behavior – taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations 
from a health care provider."112 Although the term is most often used in regards to taking 
prescribed medication, it can also refer to numerous other health-related behaviors.112 Adherence 
has a high impact on the health of patients due to its correlation with health outcomes. Low 
medication adherence can result in adverse effects, increased healthcare costs, patient frustration 
with disease and treatment, misdiagnosis, unnecessary treatment, increase in disease severity, 
increase in symptom severity, and death.113  
 
It is important to distinguish between the terms adherence and compliance. Until recently, non-
compliance was used to describe the degree to which a patient followed the directions given by 
their medical providers. The term adherence was then introduced to refer to the extent to which a 
patient's health behavior reflects their health plan which was agreed upon by both the clinician 
and the patient. Adherence is more patient attitude-centered while compliance is more clinician-
centered. Adherence also acknowledges that the patient plays a role in choosing and following 
their health plan and outcomes.114 
 
A patient's non-adherence can be categorized as intentional or unintentional. Intentional non-
adherence occurs when a patient deliberately does not take their medications for reasons such as 
to save on medication costs, lack of motivation, and belief that the medication is not efficacious. 
Unintentional non-adherence occurs when a patient lacks the capacity to follow their regimen. 
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For example, an older patient may forget to take their medications or a patient with multiple 
daily medications may not be able to take all as directed.115 
 
Non-adherence can also be categorized as primary or secondary. Primary non-adherence refers to 
when a patient is prescribed a medication but fails to fill the prescription. Primary non-adherence 
is common among patients receiving new medications. In a study of 195,930 e-prescriptions, 
researchers found that only 72% of new prescriptions were ever filled.116 Secondary non-
adherence refers to when a patient fills their prescription but does not take the dosage as 
recommended. Secondary non-adherence is usually due to patients wanting to save costs, 
forgetting to take their medications, or believing their medication is not efficacious.  
Interventions designed to improve adherence must determine which type of non-adherence the 
patient experiencing in order to effectively improve their behaviors. 
 
In 2003, the WHO concluded that non-adherence is the number one cause of preventable 
morbidity, mortality, and healthcare costs.117 It is estimated that the medication adherence rate 
across chronic diseases in the US is roughly 50%, therefore out of the 3.2 billion prescriptions 
dispensed in the US, 1.6 billion are not taken by the patients to whom they are prescribed. .112,118 
In a study conducted by Jackevicius et al., a cohort of patients with acute myocardial infarction 
were followed post-hospital discharge and only 74% of the patients filled their prescription after 
120 days.119 Another large study conducted by Vrijens et al. found that half of patients who were 
prescribed antihypertensive drugs completely stopped taking the medication after a year.120 Each 
year there are approximately 125,000 deaths in the US that can be attributed to medication non-
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adherence.121 Of the total medication-related hospital admissions in the US, it is estimated that 
between 33% and 69% are due to low adherence.118 
 
Medication non-adherence also results in unnecessary and avoidable healthcare costs. The total 
annual cost of non-adherence in the US ranges from $100 billion to $300 billion including both 
direct and indirect costs.113  In a study of Medicaid patients with heart failure, patients who were 
adherent to their medications had an overall costs 23% lower than those who were not 
adherent.122 In another study of Medicaid patients with diabetes, researchers found that for every 
10% increase in medication adherence resulted in a decline of 9-29% in total healthcare costs.123 
Low medication adherence can also result in an increase in indirect costs such as unnecessary 
caregiver costs and lost work productivity.118 
 
b. Risk factors and barriers 
Low medication adherence or non-adherence can be attributed to a variety of risk factors and 
barriers. Poor health literacy or the lack of patient understanding of their treatment plan and 
medication directions attributes to low adherence rates, demonstrating a need for patient-tailored 
medication counseling.124 
 
Medication costs have been shown to be a barrier to treatment adherence. The US is currently 
one of the leading countries with the highest pharmaceutical medication prices125 and increases 
in medication costs to the patient is associated with a decline in medication adherence.126 Almost 
75% of Americans believe that their prescription drug costs are unreasonably high and 21% find 
it difficult to pay for their prescriptions.127 In the past year, 25% of Americans have stated that 
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they or a family member have not filled their medication prescriptions in order to save money. 
An estimated 18% reported either cutting their pills in half or skipping a dose in order to save on 
medication costs.127 
 
Another factor that may lead to low adherence is the complexity of a patient's treatment regimen. 
In a study observing the medication adherence in patients prescribed statins for cardiovascular 
diseases, researchers found that a greater number of prescribers, visits to more pharmacies, a 
greater number of daily doses, and less refill consolidations were predictors of low medication 
adherence.128 Lower dosing frequencies and a lower number of medications a patient was taking 
has been found to significantly improve medication adherence.129 
 
Low medication adherence can also be attributed to the patient's cognitive beliefs. According to 
the WHO, low medication adherence has been linked to illness-relevant cognitions, perceptions 
of disease factors, and treatment beliefs. Other cognitive factors associated with medication 
adherence include perceived susceptibility of illness, perceived severity of illness, self-efficacy, 
and perceived control over the disease. Other studies have also found that patients will be more 
adherent to their medications if it results in a timely and noticeable reduction in symptom 
severity.112 
 
c. Measurements 
Medication adherence can be measured in multiple ways including direct measures, secondary 
database analyses, electronic medication packaging (EMP) devices, pill count, and clinician 
assessments and self-reports. Direct adherence measuring refers to the process of measuring the 
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medication concentration in a patient's bodily fluids such as their blood or urine. While direct 
measures are the most accurate ways to measure a patient's medication adherence, there are some 
limitations. First, the results only tell the researcher if the medication is present. There is no way 
to measure the pattern or cause of non-adherence. Direct measures are very intrusive and require 
full cooperation of the patient. Direct measures are the most expensive adherence measurement 
techniques and require scientific professionals to conduct the testing.130 
 
Secondary database analysis adherence measurement is the process of accurately estimating a 
patient's adherence levels by observing data patterns from databases such as claims databases 
and electronic prescription services. This method assumes that the patient's prescription refilling 
pattern corresponds with their medication-taking behavior. There are three types of secondary 
database analysis adherence measures: continuous variable analysis, dichotomous variable 
analysis, and consumption. Continuous variable analysis observes the patient's adherence 
behavior from the first prescription to the last prescription on record. An example of this method 
is the medication possession ratio (MPR). This method is a simple calculation of the percentage 
of days the patient received their medication over the total prescription period. MPR usually 
overestimates adherence due to its inability to adjust for gaps in refills. Dichotomous variable 
measurements label a patient as either adherent or nonadherent based on some set criteria. This 
method is the least used method and has a lower sensitivity due to the lack of a professional 
consensus of how to determine the cutoff point. Lastly, the consumption method examines the 
time between prescription refills from the perspective of gaps or periods of non-adherence. 
Examples of this method includes continuous multiple interval medication acquisition (CMA), 
continuous multiple interval medication gaps (CMG), continuous single interval medication 
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acquisition (CSA), and continuous single interval medication gap (CSG). CMA calculates 
adherence by observing the cumulative days of medication supply obtained over a series of 
intervals divided by the total number of days. CMG measures adherence by dividing the total 
number of days in treatment gaps by the total number of days. CSA measures the days of supply 
obtained in each interval over the total number of days in each interval. CSG is calculated by the 
number of days without any medication over the total number of days in the interval.130 
 
Medication adherence levels can also be measured using electronic medication packaging (EMP) 
devices. These devices are incorporated into the packaging of the medication and records doses 
taken, provides patients audio or visual reminders to take a dose, and gives feedback on the 
patient's adherence.130 While EMPs are a highly accurate method of measuring adherence, they 
are rarely used in research due to their high cost and the complex support required for use. In a 
study on adherence in patients with schizophrenia, the researchers estimated a total cost of $274 
per patient to use the devices. The authors also encountered other barriers to use such as 
encouraging patients to use the devices correctly and coordinating refills with pharmacies.131 
 
Pill counting is an indirect measure of adherence in which the number of pills left in a patient's 
prescription container is counted when they are due for a refill. This number is then divided by 
the total number of pills received to calculate an adherence ratio. This method is the least costly 
and most simplistic form of medication adherence measurement but includes several limitations. 
If a patient does not want to appear nonadherent, they may discard excess medication before 
refilling. This method also overestimates adherence due to the inability to determine if patients 
over consumed their medications.130 
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Medication adherence can be measured through clinician assessments and self-reports. This 
method is the most commonly used form of medication adherence measurement in research due 
to its relatively low cost, simplicity, and real-time feedback. Medication adherence can be 
assessed through an interview in which patients are asked to estimate their adherence rate, how 
many medication dosages they have missed, and the reasons to why they believe they are not 
adherent. A more structured form of adherence measurement can be done through the use of 
standardized or condition specific questionnaires and scales. While there is no gold standard 
measure for medication adherence, a commonly used adherence measurement is the 8-item 
Morisky Medication Adherence Scale (MMAS-8), which consists of seven yes or no questions 
related to medication adherence and one Likert scale type question/statement related to the 
frequency of the patient forgetting to take medication.132 There are multiple limitations to using 
clinician assessments and self-reporting. Patients may purposely provide false information to 
appear more adherent to their medication regimes. There is also a chance for recall bias, in which 
patients may not be able to remember the extent to their adherence. The researcher must properly 
decide which measurement to use that will most accurately measure the adherence level in their 
chosen population.130 
 
d. Adherence in the mental illness population 
Medication adherence plays a vital role in the treatment of mental illness. As stated, 
nonadherence often results in poor health outcomes, unnecessary costs, increased symptom 
severity, and treatment failure, especially in the mentally ill population. In regard to MDD, a 
retrospective chart review conducted by Sawada et al. found that 55.7% of patients with MDD 
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discontinue their antidepressant medication regimen within the first six months. In the same 
study, 55.6% of patients were found to be adherent with a MPR ≥ 0.8.133 In a retrospective, 
observational study using medical and pharmacy claims, Akincigil et al. assessed the adherence 
rates of 4,312 patients with MDD. The researchers found that 51% of the patients were adherent 
during the first 16 weeks of treatment but only 42% remained adherent within 17 to 33 weeks 
after the treatment began.134 In a retrospective study of 22,947 patients receiving a SSRI for 
MDD, Cantrell et al. found that approximately 57% of the patients were not adherent to their 
medication.135 
 
In regard to GAD, medication adherence is essential to controlling a patient’s symptoms, 
especially at the early stages of the disease. Using data collected from a community health 
survey, Bullock et al. estimated the non-adherence rate of patients prescribed anxiolytics to be 
38.1%.136 The current literature on anxiety disorder adherence rates is limited, therefore further 
research in the area is needed in order to establish accurate estimates of general adherence rates.  
 
For bipolar disorder, medication adherence is a critical part of controlling the extreme highs and 
lows of the disease. A literature review conducted by Lingam et al. observed studies that 
measured the medication adherence rates of bipolar disorder patients. The non-adherence rates 
were found to range from 20% to 60% with a median non-adherence rate of 41%. 81 In another 
large study of 140 patients receiving the mood stabilizers for bipolar disorder, Keck et al. found 
that 51% of the patients were non-adherent during the one year follow-up.137 
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Medication adherence helps prevent patients with schizophrenia from relapsing back into a 
psychotic state. The rate of relapse in schizophrenia patients who are nonadherent is 55%, which 
is significantly higher than the relapse rate of 14% for those who are adherent.138 In a study of 
100 who were patients hospitalized for acute mania, Keck et al. found that 64% of the patients 
were non-adherent to their medication the month before admission.139 
 
e. Adherence in the dual diagnosis population 
Due to the complications related to both diseases, the dual diagnosis population experiences 
unique barriers to medication adherence. Multiple studies have concluded that substance abuse is 
associated with poor medication adherence in patients with mental illnesses.140-142 Evidence 
shows this correlation may due to a variety of factors. Substance users often lead a disorganized 
lifestyle that may be intensified by a mental illness therefore resulting in difficulty following a 
regimented medication schedule. Both mental illnesses and drug use can also impair the 
cognitive functioning ability of the patient resulting in impaired judgment regarding medical 
behaviors.143 As previously stated, the mentally ill patient may be taking illicit drugs instead of 
psychotropic medications as a form of self-medication in order to subdue the side effects of the 
disease faster than their prescribed medications. A dual diagnosis patient may attribute their 
mental illness symptoms solely to drug use, and therefore not feel the need to take medications. 
The risk of non-adherence to psychotropic medication is also high due to their high risk of 
adverse events. Low adherence or sudden stopping of the medication may lead to withdraw and 
an increase in symptom severity, therefore leading the patient back to their drug use 
tendencies.144 Lastly, SUD patients may feel a stigma surrounding their mental illness 
medications, as the medication can still been seen as taking "drugs" 143 It is important to 
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recognize and treat the factors of non-adherence in the dual diagnosis population because low 
medication adherence is associated with negative health outcomes such as re-hospitalization, 
homelessness, and lower quality of life.145 Currently, there is limited literature on the adherence 
rates of the dual diagnosis population and the affects psychotropic medication adherence has on 
the health outcomes of SUD.  
 
V. Problem Statement 
Poor medication adherence is associated with negative health outcomes, especially in patients 
with mental illness and substance use disorder. Currently, there is an incomplete understanding 
of how medication adherence to psychotropics affects health outcomes of substance use 
(relapse). SUD and mental illness are two widely co-prevalent conditions with a poor 
understanding of how one affects the other. Further data on the role that medication adherence 
plays on SUD outcomes could help interventions target patients more effectively through 
specific treatment tailoring and therefore improve health outcomes of this vulnerable and 
stigmatized population.  
 
VI. Hypothesis 
The overall hypothesis of the study is that patients with low self-reported adherence rates, 
negative attitudes toward their medications, and higher severity of mental illness symptoms will 
have significantly higher relapse rates of substance abuse.  
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VII. Research Objectives 
a. Research Objective 1:  Identify personal, social, and clinical history for patients 
with substance use disorder and either major depressive disorder, bipolar disorder, 
schizophrenia, or generalized anxiety disorder 
b. Research Objective 2: Measure agreeance between patient self-report versus 
facility record history for mental illness, substance abuse, and psychotropic 
medication 
c. Research Objective 3: Investigate the specific role of medication adherence and 
barriers to use for psychotropic medications upon substance abuse relapse 
d. Research Objective 4: Assess follow-up changes in mental illness severity and 
medication adherence in dual diagnosis patients enrolled in a substance abuse 
rehabilitation program 
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CHAPTER 2 – LITERATURE REVIEW 
I. Introduction 
a. Rationale  
Patients with dual diagnosis, the co-morbid diagnosis of SUD and mental illness, exhibit more 
persistent, severe, chronic, and treatment resistant symptoms than patients with substance abuse 
disorder or a mental illness alone. Due to the severity of the disease, patients with dual diagnosis 
require unique and personalized interventions in order to improve health outcomes. The primary 
goal of interventions for patients with a substance use disorder is the avoidance of relapse, which 
is a vital health outcome of dual diagnosis treatment due to the negative consequences associated 
with substance abuse relapse.  
 
Poor medication adherence is associated with negative health outcomes in many chronic diseases 
including the dual diagnosis population. Patients with mental illness are at a higher risk of 
nonadherence due to their lack of awareness of the disease and the significant side effects of 
psychotropic medication. Patients with SUD are at a high risk of nonadherence due to the 
interaction between illicit drugs and psychotropics, the patient’s lifestyle choices, the effect of 
drug use on memory, and self-medication with illicit drugs. The combination of both a mental 
illness and a substance use disorder diagnosis only amplifies the risk of nonadherence therefore 
leading to poor health outcomes. Therefore, it would be assumed that medication adherence 
would be an important focus of dual diagnosis treatment yet there is currently an incomplete 
research understanding of exactly how medication adherence to psychotropic medications 
impacts the therapeutic outcomes of patients with dual diagnosis, especially substance use 
relapse.  
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b. Objectives 
The objectives of the literature review were to: (1) identify published studies that evaluate the 
relationship between substance abuse, psychotropic medications, and medication adherence, and 
(2) identify gaps in the existing literature.  
 
II. Methods 
a. Search strategy 
The systematic literature review was conducted according to the Preferred Reported Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Peer-reviewed journals were 
assessed using the electronic databases PubMed (1996-present), SCOPUS (1990-present), and 
PsychINFO (2001-present). The last search was run on March 1st, 2017. Articles that were not 
available online were requested and received through the Duquesne University Gumberg 
Library. Article eligibility assessment was performed independently by one reviewer and 
uncertainty in regard to an article’s eligibility was resolved by a consensus between the reviewer 
and the thesis committee chair. A data extraction sheet was developed using Microsoft Excel 
(Redmond, WA), including the following from each article: (1) study objectives, (2) year 
published, (3) study population characteristics, (4) study location, (5) methodology, (6) relevant 
outcomes, (7) self-reported limitations.  
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b. Eligibility criteria 
The inclusion criteria for the literature review were primary research articles assessing the 
relationship between substance abuse, psychotropic medications, and adherence. Review articles, 
grey literature, and non-English articles were excluded.  
 
c. Search terms 
The search terms used for the PubMED search were as follows: 
(Antipsychotic[tiab] OR Antipsychotics[tiab] OR Neuroleptic[tiab] OR Neuroleptics[tiab] 
OR Psychotropic[tiab] OR Psychotropics[tiab] OR Antischizophrenic[tiab] OR 
Antidepressant[tiab] OR Antianxiety[tiab] OR "Antipsychotic Agents" [Pharmacological 
Action] OR "Antipsychotic Agents"[Mesh]) AND (“Drug Dependence”[tiab] OR “Drug 
Addiction”[tiab] OR “Drug Habituation”[tiab] OR “Substance Use Disorders”[tiab] OR 
“Substance Use Disorder”[tiab] OR “Substance Abuse”[tiab] OR “Substance Abuses”[tiab] 
OR “Substance Dependence”[tiab] OR “Substance Addiction”[tiab] OR “Drug Abuse”[tiab] 
OR “Drug Use Disorders”[tiab] OR “Drug Use Disorder”[tiab] OR "Substance-related 
disorders"[MH]) AND (Adherence[tiab] OR Non-Compliance[tiab] OR 
Noncompliance[tiab] OR Non-adherence[tiab] OR Nonadherence[tiab] OR "Patient 
Compliance"[Mesh:NoExp] OR "Medication Adherence"[Mesh]) 
 
The search terms used for the SCOPUS search were as follows: 
TITLE-ABS-KEY  (Antipsychotic OR Antipsychotics OR Neuroleptic OR Neuroleptics OR 
Psychotropic OR Psychotropics OR "Antipsychotic Agents" OR "Antipsychotic Agents”) 
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AND TITLE-ABS-KEY  (“Drug Dependence” OR “Drug Addiction” OR “Drug 
Habituation” OR “Substance Use Disorders” OR “Substance Use Disorder” OR “Substance 
Abuse” OR “Substance Abuses” OR “Substance Dependence” OR “Substance Addiction” 
OR “Drug Abuse” OR “Drug Use Disorders” OR “Drug Use Disorder” OR "SUBSTANCE-
RELATED DISORDERS”) AND TITLE-ABS-KEY  (Adherence OR Non-Compliance OR 
Noncompliance OR Non-adherence OR Nonadherence OR "Patient Compliance” OR 
"Medication Adherence”) 
 
The search terms for the PsycINFO search were as follows: 
(DE "Neuroleptic Drugs") AND (DE "Drug Abuse" OR DE "Alcohol Abuse" OR DE "Drug 
Dependency" OR DE "Inhalant Abuse" OR DE "Polydrug Abuse" OR DE "Drug Addiction" 
OR DE "Heroin Addiction" OR DE "Substance Use Disorder") AND (DE "Treatment 
Compliance") 
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III. Results 
a. Study selection 
The results of the search are shown in the PRISMA flowchart depicted in Figure 1. 
Figure 1: Results of the Literature Search 
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b. Study characteristics  
A total of 51 studies were included in the synthesis of the literature review. The publication dates 
of the articles ranged from 1990 to 2017. The largest study contained a sample of 44,026 patients 
and the smallest study contained a sample of 42 patients. Methods utilized to collect data 
included structured in-person interviews, self-reported questionnaires, mailed surveys, medical 
claims database analysis, medical chart reviews, clinical assessments, and randomized clinical 
trials.  
 
Of the 51 studies included, 32 were conducted in the US (63%), four in Canada (8%), three in 
Spain (6%), two in Ireland (4%) and two in UK (4%). Other countries with a single article (2% 
each) included in the review were Germany, Israel, Nigeria, Denmark, Australia, Norway and 
Italy. One multi-country study (2%) took place in Spain, UK and Greece. 
 
The review contained studies assessing multiple mental illness populations. Schizophrenia was 
the most reported mental illness in the review (20 articles, 40%). Other mental illnesses studied 
included bipolar disorder (9, 18%), psychosis (4, 8%), MDD (3, 6%) and post-traumatic stress 
disorder (1, 2%). Two studies (4%) observed patients with either schizophrenia or bipolar 
disorder. Two studies (4%) assessed patients with psychotic disorders in general and two other 
studies (4%) assessed patients with any DSM-IV mental illness. Of the 51 total studies, 8 (16%) 
specifically observed the dual diagnosis population.  
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c. Results of individual studies 
 
A summary of studies identified by the systematic literature review are in Table 1.
  
4
6
 
Table 1: Details of Individual Studies Identified in the Systematic Review 
Authors, Year Objective* Study Population Location Methods Relevant Outcomes Limitations 
Akincigil A, Bowblis 
JR, Levin C, Walkup 
JT, Jan S, Crystal S 
2007 134 
To describe patient 
and provider level 
factors associated 
with treatment 
adherence in patients 
with major 
depressive disorder 
4312 patients who initiated 
antidepressant treatment 
US 
 
Retrospective, 
claims database 
analysis 
Lower adherence was 
associated with alcohol abuse 
(OR=0.49) and other substance 
abuse (OR=0.72). 
Limited 
generalizability, 
recall bias, 
desirability bias 
Ascher-Svanum H, 
Faries D, Zhu B, Ernst 
FR, Swartz MS, 
Swanson JW 2006 146 
To examine the 
relationship between 
adherence to 
antipsychotic 
medications and 
functional outcomes 
among schizophrenia 
patients 
1906 participants with 
schizophrenia or 
schizoaffective or 
schizophreniform disorder 
US 
Prospective, 
interview and 
medical record 
analysis 
Non-adherent patients were 
more likely to consume drugs or 
alcohol (OR=1.36) 
Adherence measure 
may be inaccurate 
Ascher-Svanum H, 
Zhu B, Faries D, 
Lacro JP, Dolder CR 
2006 147 
Identify predictors of 
nonadherence to 
psychotropic 
medication in 
patients with 
schizophrenia 
1579 patients in the US 
Schizophrenia Care and 
Assessment Program 
US 
Prospective, 
interview and 
medical record 
analysis 
Predictors of nonadherence 
were illicit drug use 4 weeks 
prior to treatment (OR=1.8) and 
alcohol use 4 weeks prior to 
treatment (OR=1.6) 
Not all potential 
factors measured 
Baldessarini RJ, Perry 
R, Pike J 2008 148 
To determine the risk 
factors that lead to 
nonadherence in 
patients with bipolar 
disorder 
429 adults with bipolar 
disorder 
US 
Cross-sectional, 
questionnaire 
Alcohol dependence was a 
factor significantly associated 
with nonadherence (RR=2.26) 
Recall bias 
Coldham EL, 
Addington J, 
Addington D 2002 149 
To measure 
adherence rates to 
antipsychotic 
medications in first 
episode psychosis 
patients 
200 patients (132 males, 68 
females) in the Calgary Early 
Psychosis Program with a 
first episode of psychosis 
Canada 
Prospective, 
interview 
Cannabis is a predictor of 
nonadherence (OR=0.46). 
Alcohol use was significantly 
associated with nonadherence 
(p=.02) 
Recall bias 
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Colizzi M, Carra E, 
Fraietta S, Lally J, 
Quattrone D, 
Bonaccorso S, 
Mondelli V, Ajnakina 
O, Dazzan P, Trotta 
A, Sideli L, Kolliakou 
A, Gaughran F, 
Khondoker M, David 
AS, Murray RM, 
MacCabe JH, Di Forti 
M 2005 150 
To clarify the 
contribution 
substance use and 
poor medication 
adherence to poor 
outcomes after a first 
episode of psychosis 
205 patients with a first 
episode psychosis 
UK 
Prospective, 
interview and 
database analysis 
Nonadherence was significantly 
associated with nicotine 
dependence (OR=2.18), 
cannabis use (OR=2.86), and 
stimulant use (OR=2.63) but not 
problem drinking. 
Recall bias, social 
desirability  
Cooper D, Moisan J, 
Grégoire J-P 2005 151 
To identify 
determinants of 
compliance among 
patients with 
schizophrenia 
6662 individuals with 
schizophrenia initiated on 
treatment with atypical 
antipsychotics 
Canada 
Prospective, 
database analysis 
Patients without a history of 
substance-use disorder were 
more likely to be both persistent 
(OR=0.70) and compliant 
(OR=0.63) to their medications 
Adherence 
measurement may be 
inaccurate 
Elbogen EB, Swanson 
JW, Swartz MS, Van 
Dorn R 2005 152 
To examine the 
effect depressive 
symptoms and social 
stability have on 
nonadherence in 
psychosis 
528 adults with psychotic 
disorders receiving treatment 
from public mental health 
systems 
US 
Cross-sectional, 
interview 
Substance abuse was a predictor 
for nonadherence (OR=2.04) 
Could not establish 
temporality 
González-Pinto A, 
Reed C, Novick D, 
Bertsch J, Haro JM. 
2010 153 
To identify factors 
associated with 
medication 
adherence in bipolar 
disorder patients 
1,831 bipolar disorder 
patients either starting or 
switching treatment for a 
manic/mixed episode 
Spain 
Prospective, 
interview 
Nonadherence is associated 
with patients with cannabis 
abuse/dependence 
Adherence 
measurement may 
not be accurate  
Grunebaum MF, 
Weiden PJ, Olfson M 
2001 154 
To examine the 
association between 
medication 
adherence and level 
of supervision along 
with other 
environmental and 
clinical variables  
74 adult residents with 
schizophrenia and related 
psychotic disorders living in 
supported housing facilities 
US 
Cross-sectional, 
interview 
Drug and alcohol abuse was not 
associated with adherence 
Could not establish 
causation 
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Herbeck DM, Fitek 
DJ, Svikis DS, 
Montoya ID, Marcus 
SC, West JC 2005 155 
To examine clinical 
and non-clinical 
factors associated 
with treatment 
compliance problems 
in patients with 
comorbid psychiatric 
and substance use 
disorders 
342 patients with comorbid 
psychiatric and substance use 
disorders 
US 
Cross-sectional, 
questionnaire  
A comorbid personality 
disorder (OR=2.6), lower 
functioning ability (OR-3.6), a 
current illicit drug problem 
(OR=4.0), and medication side 
effects (OR=2.5) were strongly 
associated with noncompliance 
Small sample size, 
could not establish 
temporality  
Hill M, Crumlish N, 
Whitty P, Clarke M, 
Browne S, Kamali M, 
Kinsella A, 
Waddington JL, 
Larkin C, 
O'Callaghan E 2010 
156 
To examine 
associations and 
predictors of 
nonadherence to 
antipsychotics four 
years after a first 
episode of psychosis 
171 patients with a first 
episode of psychosis 
Ireland 
Prospective, 
interview 
Alcohol or drug misuse at 
baseline were predictors of 
nonadherence at 4 years 
(OR=6.9) 
Adherence 
measurement may be 
inaccurate  
 
Hunt GE, Bergen J, 
Bashir M 2002 157 
To examine the 
effect of medication 
compliance and 
substance abuse on 
schizophrenia 
outcomes 
99 patients with 
schizophrenia receiving 
acute care in a hospital or a 
24-hour community-based 
crisis teams 
Australia 
Prospective, 
medical record 
analysis 
Medication noncompliance 
(HR=2.46) and current 
substance abuse (HR=1.83) 
were predictors of 
hospitalization 
Limited 
generalizability, 
small sample size 
Iasevoli F, Fagiolini A, 
Formato MV, 
Prinzivalli E, 
Giordano S, Balletta 
R, De Luca V, de 
Bartolomeis A 2017 158 
To evaluate the 
consistency, 
reliability, and 
determinants of two 
real-world measures 
of adherence to 
prescription in 
schizophrenia 
patients 
57 schizophrenia patients and 
61 non-schizophrenia 
patients 
Italy 
Cross-sectional, 
interview 
Substance abuse was a 
significant predictor of lower 
adherence scores (p=0.027) 
Small sample size 
Janssen B, Gaebel W, 
Haerter M, 
Komaharadi F, Lindel 
B, Weinmann S 2006 
159 
To evaluate patient-
related and 
treatment-related 
factors associated 
with medication 
compliance in 
inpatients with a 
psychotic disorder 
670 patients with 
schizophrenia, 
schizoaffective disorder, or 
another psychotic disorder 
Germany 
Prospective, 
interview 
Substance abuse was a predictor 
for nonadherence (OR=0.52) 
Nonrandomized, 
adherence 
measurement not 
validated  
Jónsdóttir H, 
Opjordsmoen S, 
Birkenaes AB, 
Simonsen C, Engh JA, 
To investigate 
potential risk factors 
for medication non-
adherence in patients 
255 patients with 
schizophrenia or bipolar 
disorder 
Canada 
Cross sectional, 
clinical 
assessments and 
blood sampling 
A previous diagnosis of 
substance abuse or addiction 
was associated with 
nonadherence in both the 
Could not establish 
temporality, 
Hawthorne effect 
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Ringen PA, Vaskinn 
A, Friis S, Sundet K, 
Andreassen OA 2013 
160 
with schizophrenia 
and bipolar disorder 
bipolar and schizophrenic 
groups 
Kamali M, Kelly L, 
Gervin M, Browne S, 
Larkin C, 
O'Callaghan E 2001 
161 
To examine factors 
related to 
noncompliance to 
oral antipsychotics in 
patients with 
schizophrenia 
87 patients with 
schizophrenia or 
schizoaffective disorder 
readmitted to a hospital with 
acute psychotic relapse 
US 
Cross-sectional, 
interview 
Comorbid substance abuse is a 
predictor of noncompliance 
(p=.003). 
Adherence 
measurement may 
not be accurate 
Kamali M, Kelly BD, 
Clarke M, Browne S, 
Gervin M, Kinsella A, 
Lane A, Larkin C, 
O'Callaghan E 2006 
162 
To identify factors of 
first episode 
schizophrenia that 
predict adherence at 
six-month follow-up 
100 patients with a diagnosis 
of schizophrenia 
Ireland 
Prospective, 
interview 
Alcohol misuse and drug 
misuse were predictors of non-
adherence at six months follow-
up 
Low follow-up rate, 
compliance 
measurements may 
not be accurate 
Keck PE Jr, McElroy 
SL, Strakowski SM, 
Bourne ML, West SA. 
1997 137 
To measure the rates 
of noncompliance in 
patients with bipolar 
disorder 
140 patients hospitalized for 
bipolar disorder 
US 
Prospective, 
questionnaire 
Noncompliance was 
significantly associated 
comorbid substance use 
disorder 
Adherence 
measurement may 
not be accurate 
Krivoy A, Malka L, 
Fischel T, Weizman A, 
Valevski A 2011 163 
To identify the 
clinical parameters 
that could predict 
clozapine 
discontinuation in 
patients with 
schizophrenia 
100 patients with 
schizophrenia who were 
hospitalized and prescribed 
clozapine 
Israel 
Retrospective, 
medical record 
analysis 
 
Comorbid substance abuse is a 
predictor for drug 
discontinuation 
Small sample size, 
limitations 
associated with 
retrospective studies 
Lagerberg TVV, 
Andreassen OA, 
Ringen PAA, Berg 
AO, Larsson S, Agartz 
I, Sundet K, Melle I. 
2010 164 
To investigate the 
lifetime rates of 
substance use in 
bipolar disorder 
patients and identify 
clinical outcome 
differences 
125 bipolar disorder patients 
and 327 population reference 
Norway 
Retrospective, 
interview 
 
Bipolar patients were 
significantly more likely to use 
illicit substances compared to 
the general population 
(OR=3.03). Patients with 
excessive substance use had 
significantly lower adherence 
(p=0.01) 
Small sample size, 
could not establish 
causation 
Lang K, Meyers JL, 
Korn JR, Lee S, 
Sikirica M, Crivera C, 
Dirani R, Menzin J 
2010 165 
To assess adherence 
rates and predictors 
of nonadherence and 
hospitalization 
among patients with 
schizophrenia 
12,032 Florida Medicaid 
patients with schizophrenia 
receiving a long-acting 
injectable and oral 
antipsychotic 
US 
Retrospective, 
claims database 
analysis 
A substance abuse diagnosis is 
a predictor of nonadherence 
(OR=1.54) 
Diagnosis not 
verified, adherence 
measurement may 
not be accurate 
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Lecomte T, Spidel A, 
Leclerc C, MacEwan 
GW, Greaves C, 
Bentall RP 2008 166 
To assess constructs 
that may be linked to 
medication 
adherence in patients 
with early psychosis 
118 early psychosis patients Canada 
Cross-sectional, 
interview 
No significant link between 
adherence and substance abuse 
disorder 
Limited 
generalizability, 
adherence 
measurement may 
not be accurate 
Liu X, Chen Y, Faries 
DE 2011 167 
To compare 
adherence of three 
antidepressants and 
examine predictors of 
adherence in patients 
with major 
depressive disorder 
44,026 patients diagnosed 
with major depressive 
disorder and prescribed an 
SSRI 
US 
Retrospective, 
claims database 
analysis 
Alcohol dependence (OR=0.75) 
and drug dependence 
(OR=0.66) were associated with 
decreased adherence 
Selection bias, 
adherence 
measurement may 
not be accurate 
Lloyd A, Horan W, 
Borgaro SR, Stokes 
JM, Pogge DL, 
Harvey PD 2009 168 
To determine 
predictors of 
medication 
compliance in 
psychiatric patients 
97 adolescent psychiatric 
patients 
US 
Prospective, 
questionnaire 
Post discharge substance abuse 
is a predictor of nonadherence 
(p<0.10) 
Participants taken 
from previous 
substance abuse 
study 
Lockwood A, Steinke 
DT, Botts SR 2009 169 
To evaluate 
adherence and its 
effect on relapse 
among veterans with 
PTSD 
82 veterans diagnosed with 
PTSD 
US 
Retrospective, 
claims database 
analysis 
Comorbid substance abuse was 
not associated with drug 
adherence 
Diagnosis not 
confirmed, 
adherence 
measurement may 
not be accurate 
MacEwan JP, Forma 
FM, Shafrin J, Hatch 
A, Lakdawalla DN, 
Lindenmayer JP 2016 
170 
To identify patterns 
of medication 
adherence over time 
for patients with 
schizophrenia 
29,607 patients with an oral 
atypical antipsychotic 
US 
Prospective, 
database analysis 
Patients with a history of drug 
abuse (OR=1.46) and alcohol 
abuse (OR=1.34) were more 
likely to be less adherent 
Potential coding 
errors, limited 
generalizability  
Magura S, Laudet AB, 
Mahmood D, 
Rosenblum A, Knight 
E 2002 171 
To examine 
associations between 
self-help meeting 
attendance, 
medication 
adherence, and 
mental health 
outcomes in those 
with a dual diagnosis 
240 Double Tree in 
Recovery (DTR) self-help 
group participants with both 
chronic mental illness and a 
substance abuse disorder 
US 
Prospective, 
interview 
Living in supported housing, 
having fewer stressful life 
events, and having a lower 
severity of psychiatric 
symptoms were associated with 
adherence 
Nonstandardized 
measures, adherence 
measurement may be 
inaccurate 
Magura S, Mateu PF, 
Rosenblum A, 
Matusow H, Fong C 
2014 172 
To examine the risk 
factors of 
nonadherence in 
psychiatric patients 
with substance 
misuse history 
229 patients with a mental 
illness, a history of substance 
misuse, and a current 
prescription for psychiatric 
medication 
US 
Cross-sectional, 
interview 
Lower adherence was 
associated with medication side 
effects, excessive alcohol use, 
and a diagnosis of depression. 
Schizophrenia was associated 
with higher adherence 
Limited 
generalizability, 
could not establish 
causation 
  
5
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Magura S, Rosenblum 
A, Fong C 2011 173 
To measure and 
determine factors 
related to 
nonadherence in 
psychiatric patients 
with substance abuse 
histories  
131 patients in a psychiatric 
continuing day treatment 
program who had substance 
misuse histories and are 
prescribed psychiatric 
medication 
US 
Cross-sectional, 
interview 
Factors correlated with lower 
adherence in the substance 
misuse population were: lower 
social support for quitting 
drug/alcohol, lower recovery-
promoting behaviors, 
nonsatisfaction with 
medication, medication side 
effects, lower self-efficacy for 
drug avoidance, and lower 
social support for recovery 
Limited 
generalizability, 
could not establish 
causation 
Manwani SG, Szilagyi 
KA, Zablotsky B, 
Hennen J, Griffin ML, 
Weiss RD 2007 174 
To examine patterns 
of adherence to mood 
stabilizers in patients 
with bipolar disorder 
115 bipolar disorder patients 
(58 with SUD and 57 without 
SUD) 
US 
Cross-sectional, 
interview 
Patients with co-occurring SUD 
were less adherent than those 
without 
Adherence 
measurement may be 
inaccurate  
Miller R, Ream G, 
McCormack J, 
Gunduz-Bruce H, 
Sevy S, Robinson D. 
2009 175 
To determine if 
cannabis use is a risk 
factor of 
nonadherence 
112 first-episode 
schizophrenia patients 
US 
Prospective, 
interview 
Cannabis use significantly 
increased nonadherence 
(HR=2.4) 
Limited 
generalizability, use 
of other substances 
not observed 
Montes JM, Maurino 
J, de Dios C, Medina 
E 2013 176 
Identify factors 
associated with 
adherence in patients 
with bipolar disorder 
303 outpatients on oral 
antipsychotics 
Spain 
Cross-sectional, 
interview 
Substance abuse/dependence 
was a predictor of low treatment 
adherence (OR=1.95). 
Could not establish 
causation, limited 
generalizability, 
adherence measures 
may be inaccurate 
Murru A, Pacchiarotti 
I, Amann BL, Nivoli 
AM, Vieta E, Colom F 
2013 177 
To compare 
correlations between 
adherence and the 
course of illness in 
bipolar and 
schizophrenia 
patients 
50 Patients with bipolar 
disorder type I and 75 
patients with schizoaffective 
disorder, bipolar type 
Spain 
Cross-sectional, 
prospective, and 
retrospective, 
interview 
No association between poor 
adherence and substance abuse 
Could not establish 
causation, limited 
generalizability  
Novick D, Haro JM, 
Suarez D, Perez V, 
Dittmann RW, 
Haddad PM 2010 178 
To assess the 
predictors of 
antipsychotic 
adherence during 
long-term 
schizophrenia 
treatment 
6731 outpatients with 
schizophrenia who were 
starting or switching 
antipsychotics for clinical 
reasons 
Spain, 
UK, 
Greece 
Prospective, 
interview 
Current alcohol dependence 
(OR=0.63) and substance abuse 
(OR=0.67) were predictors of 
nonadherence 
Adherence 
measurement may be 
inaccurate  
Okpataku CI, 
Kwanashie HO, 
Ejiofor JI, Olisah VO 
2015 179 
To determine 
medication 
adherence behavior 
in psychiatric out-
patients with 
208 psychiatric out-patients 
with psychoactive substance 
use in a Nigerian Tertiary 
Hospital 
Nigeria 
Cross-sectional, 
interview 
No relationship was found 
between substance use and 
medication adherence 
No limitations 
reported 
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psychoactive 
substance use 
comorbidity 
Olfson M, Mechanic 
D, Hansell S, Boyer 
CA, Walkup J, 
Weiden PJ 2000 180 
To identify predictors 
of medication 
noncompliance in 
patients with 
schizophrenia 
213 adult psychiatric 
inpatients with a diagnosis of 
schizophrenia or 
schizoaffective disorder 
prescribed antipsychotics 
US 
Prospective, 
interview 
A substance use disorder was a 
predictor of medication 
noncompliance (OR=4.6) 
Recall bias, social 
desirability  
Owen RR, Fischer EP, 
Booth BM, Cuffel BJ 
1996 181 
To examine the 
effect of medication 
noncompliance and 
substance abuse on 
symptoms of 
schizophrenia 
Short-term inpatients 
schizophrenia 
US 
Prospective, 
interview 
Noncompliance was associated 
with substance abuse 
None reported 
Perkins DO, Gu H, 
Weiden PJ, McEvoy 
JP, Hamer RM, 
Lieberman JA 2008 182 
To evaluate 
predictors of 
medication 
nonadherence in 
patients recovering 
from a first episode 
of psychosis 
400 patients with 
schizophrenia, 
schizophreniform disorder, 
or schizoaffective disorder 
US Prospective, RCT 
Ongoing substance abuse was a 
predictor of poor medication 
adherence (p<.01) 
Limited 
generalizability  
Pogge DL, Singer MB, 
Harvey PD 2005 183 
To examine 
antipsychotic 
medication 
adherence of 
adolescents 
86 adolescent inpatients 
prescribed olanzapine or 
risperidone 
US 
Retrospective, 
interview 
A diagnosis of substance abuse 
was significantly related to 
nonadherence 
Limited 
generalizability   
Pristach CA, Smith 
CM 1990 184 
To examine the 
relationship between 
patterns of alcohol 
and drug use and 
compliance to 
medication among 
schizophrenia 
patients 
42 schizophrenic patients in 
an acute care psychiatric unit 
US 
Cross-sectional, 
interview 
No significant difference in 
compliance between alcohol 
users and non-users 
Could not 
distinguish between 
past and current 
alcohol use 
Quach PL, Mors O, 
Christensen TØ, 
Krarup G, Jørgensen 
P, Bertelsen M, 
Jeppesen P, Petersen 
L, Thorup A, 
Nordentoft M 2009 185 
To identify predictors 
of poor medication 
adherence among 
patients with first-
episode 
schizophrenia-
spectrum disorder 
547 patients with first-
episode schizophrenia-
spectrum disorder 
Denmark 
Prospective, 
interview 
Substance abuse was a predictor 
of low adherence (OR=2.03) at 
1-year follow-up 
None reported 
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Sajatovic M, Bauer 
MS, Kilbourne AM, 
Vertrees JE, Williford 
W 2006 186 
To evaluate factors 
related to treatment 
adherence among 
veterans with bipolar 
disorder 
430 veterans diagnosed with 
bipolar disorder 
US 
Cross-sectional, 
interview 
A current substance use 
disorder was a predictor of 
nonadherence (p=.007) but any 
past substance use disorder was 
not 
Low sample size, 
adherence 
measurement may 
not be accurate 
Sajatovic M, Blow FC, 
Kales HC, Valenstein 
M, Ganoczy D, 
Ignacio RV 2007 187 
To evaluate patients 
receiving 
antipsychotic 
medication using the 
medication 
possession ratio 
(MPR) 
26,530 younger individuals 
and 6,461 older individuals 
prescribed antipsychotic 
medication 
UK 
Retrospective, 
database analysis 
Substance abuse was a predictor 
of nonadherence in the older 
population (OR=1.38) and the 
younger population (OR=1.30) 
Adherence 
measurement may 
not be accurate  
Sajatovic M, Ignacio 
RV, West JA, Cassidy 
KA, Safavi R, 
Kilbourne AM, Blow 
FC 2009 188 
To examine clinical 
and subjective 
variables in relation 
to adherence in 
bipolar patients 
140 patients with bipolar 
disorder treated with mood 
stabilizers in a mental health 
clinic 
US 
Cross-sectional, 
interview 
Comorbid substance abuse is a 
predictor of low adherence 
(p<.01) 
Cross-sectional 
design limitations, 
small sample size, 
adherence 
measurement may 
not be accurate  
Sajatovic M, 
Valenstein M, Blow 
FC, Ganoczy D, 
Ignacio RV 2006 189 
To examine 
adherence with 
psychotropic 
medications among 
patients with bipolar 
disorder 
32,993 veterans diagnosed 
with bipolar disorder  
US 
Retrospective, 
database analysis 
Comorbid substance abuse 
associated with treatment non-
adherence (p<.0001) 
Retrospective design 
limitations, gender 
homogeneity, 
inability to validate 
medical records 
Swanson AJ, Pantalon 
MV, Cohen KR 1999 
190 
To investigate the 
effect of motivational 
interviewing on 
adherence among 
psychiatric and 
dually diagnosed 
inpatients 
121 psychiatric inpatients, 93 
with a history of substance 
abuse/dependence disorder 
US 
Prospective, 
assessment of 
motivational 
interviewing 
intervention  
Brief motivational interventions 
improve adherence among 
dually diagnosed patients 
Limited 
generalizability, no 
control group 
Swartz MS, Swanson 
JW, Hiday VA, 
Borum R, Wagner 
HR, Burns BJ 1998 191 
To examine the joint 
effect of substance 
abuse and medication 
noncompliance in 
regard to the risk of 
violent acts 
331 in patients with severe 
mental illness 
US 
Cross-sectional 
and retrospective, 
interview and 
other data drawn 
from a RCT 
The combination of 
noncompliance and 
alcohol/substance abuse is 
associated with serious violent 
acts (p<.01) 
Limited 
generalizability, 
could not establish 
temporality  
Teter CJ, Falone AE, 
Bakaian AM, Tu C, 
Ongür D, Weiss RD 
2013 192 
To examine the 
impact of substance 
use disorder among 
patients with bipolar 
disorder in regard to 
medication taking 
behaviors 
54 bipolar I disorder patients 
at the Schizophrenia and 
Bipolar Disorder Program at 
McLean Hospital 
US 
Cross-sectional, 
interview 
Patients with a past history of 
SUD are more likely to adhere 
to their medication regimen as 
compared to patients with a 
current SUD 
Small sample size, 
low generalizability  
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Wilk J, Marcus SC, 
Westt J, Countis L, 
Hall R, Regier DA, 
Olfson M 2006 193 
To compare clinical 
characteristics of 
nonadherence among 
schizophrenia 
patients with and 
without past 
comorbid substance 
use disorders 
190 patients with 
schizophrenia and 105 with a 
comorbidity of SUD and 
schizophrenia 
US 
Cross-sectional, 
questionnaire 
Patients with a substance use 
disorder were less likely to 
discuss the risks of 
nonadherence with their 
provider (p=0.05), link 
adherence to personal goals 
(p=.006), or explore the 
meaning of taking antipsychotic 
medications with their provider 
(p=0.01) 
Adherence 
measurement may 
not be accurate, no 
clinical diagnosis, 
limited 
generalizability  
Zivin K, Ganoczy D, 
Pfeiffer PN, Miller 
EM, Valenstein M 
2009 194 
To assess predictors 
of antidepressant 
adherence among 
depressed veterans 
20,931 and 23,182 veterans 
registered in the VA who 
have major depressive 
disorder and received 
antidepressants 
US 
Prospective, 
database analysis 
Patients with a substance abuse 
disorder were more likely to 
have poorer adherence at both 3 
months (OR=2.18) and 6 
months (OR=2.36) 
Adherence 
measurement may be 
inaccurate  
*Objectives directly reported from literature 
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d. Synthesis of results  
Of the 51 studies included in the literature review, 36 studies (71%) concluded that 
comorbid substance use was significantly associated with psychotropic medication 
nonadherence.134,137,146-149,151-153,155,156,158-165,167,168,170,174-176,178,180-183,185-189,194 Eighteen of 
these studies (35%) identified substance use as a predictor of 
nonadherence.149,152,156,158,159,161-163,165,168,176,178,180,182,185-188 The rest simply found an 
association between the two variables. Of these 35 studies, nine (18%) identified alcohol 
abuse specifically as a factor associated with nonadherence134,147-149,156,162,167,170,178 and 
three (6%) identified cannabis use as a factor.149,153,175 In regard to negative outcomes, six 
studies (12%) found no significant relationship between substance use and psychotropic 
medication adherence.154,166,169,177,179,184 Of these six studies, 1 (2%) specifically observed 
alcohol use and found no relationship with nonadherence.184 One study (2%) included in 
the review found mixed results of both negative and positive outcomes.150 This study 
conducted by Colizzi et al. observed 205 patients with a first episode of psychosis in 
order to identify the effect substance use and poor medication adherence has on health 
outcomes. The researchers concluded that nonadherence was significantly associated with 
nicotine dependence (OR=2.18), cannabis use (OR=2.86), and stimulant use (OR=2.63) 
but was not associated with problem drinking. The remaining eight studies (16%) 
identified additional conclusions that are further explained below.157,171-173,190-193  
 
As stated, eight studies (16%) specifically observed the dual diagnosis population.155,171-
174,179,190,193 Two of these studies found a significant relationship between substance use 
and nonadherence and one found no significant relationship. The first study, conducted 
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by Herbeck et al., examined 342 patients with comorbid psychiatric and substance use 
disorder and concluded that a current illicit drug problem was significantly associated 
with nonadherence (OR=4.0).155 The second, conducted by Manwani et al., examined the 
adherence patterns to mood stabilizers in 115 patients with bipolar disorder, of which 58 
had a SUD and 57 did not. The researchers found that lifetime adherence was 
significantly lower in the SUD group (65.9%) versus the non-SUD group (85.0%).174 
Lastly, Okpataku et al. conducted a study in a Nigerian Tertiary Hospital observing 
medication adherence behaviors in psychiatric outpatients with psychoactive substance 
use comorbidities. The researchers found no statistically significant relationship between 
substance use and medication adherence.179  
 
Out of the eight studies observing the dual diagnosis population, five studies aimed to 
identify the factors associated with psychotropic mediation nonadherence in patients with 
dual diagnosis.134,171-173,193 The factors found to be associated with a higher level of 
adherence included living in supported housing, having fewer stressful life events, and 
lower mental illness symptom severity. Factors associated with lower adherence levels 
were lower social support for drug and alcohol abstinence, less recovery-promoting 
behaviors, lower satisfaction with medication, more severe medication side effects, lower 
self-efficacy for drug avoidance, lower social support for recovery, the diagnosis of a 
comorbid personality disorder versus other mental illnesses, lower functioning ability, 
and the current use of illicit substances. The studies specific to the dual-diagnosis 
population also concluded that these patients were less likely to discuss the risks of 
nonadherence with their healthcare provider (p=.05), less likely to link adherence to their 
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personal healthcare goals (p=.006), and less likely to explore the purpose of their 
psychotropic medications with their healthcare provider (p=.01) when compared to 
psychiatric patients without a comorbid substance use disorder.  
 
The last study to observe the dual diagnosis population was conducted by Swanson et al. 
The objective of the study was to investigate the effect motivational interviewing has on 
adherence among the psychiatric and dual diagnosis population. The 121 enrolled 
patients were split into two groups; one group received a standard treatment using 
pharmacological and psychosocial methods while the second group received a standard 
treatment along with an hour-long motivational interview given by a staff therapist. The 
results showed that a significantly greater proportion of the motivational interview group 
adhered to their treatment regimen after discharge. The researchers concluded that brief 
motivational interventions show potential as effective tools for improving adherence in 
the dual diagnosis population.190   
 
The three remaining studies did not observe the dual-diagnosis population but did 
identify additional conclusions.  Swartz et al. set out to examine the effect of substance 
abuse combined with medication nonadherence in regard to the risk of violent acts. 331 
patients with severe mental illnesses were recruited from a previous randomized control 
trial on involuntary outpatient commitment. Through face-to-face and telephone 
interviews, the patients were asked questions related to violent acts such as whether they 
have been arrested for physical or sexual assault, have gotten into a physical altercation 
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that involved violent actions, or done anything that would cause a person to be afraid of 
being harmed. Serious violent acts were defined as a violent act or a threat involving a 
weapon or that resulted in an injury of another person. Adherence was measured through 
self-report or the report of a family member. The researchers concluded that the 
combination of nonadherence and alcohol or substance abuse is significantly associated 
with serious violent acts (OR=2.29).191  
 
In a study conducted by Teter et al., 54 inpatients who were hospitalized for bipolar 
disorder were interviewed in order to examine the impact of substance use on medication 
adherence. Psychiatric symptom rating scaled were administered in order to assess the 
patient’s mental illness severity. Medication taking behaviors were observed daily by the 
researchers and a standardized medication adherence ratio (SMAR) was calculated. 
Patients were split into three categories; no substance use history, past substance use 
history, and current substance use. The results showed that the SMAR of patients in the 
current substance use group was significantly lower than patients in either the no 
substance use history group or the past substance use history group.192  
 
Lastly, Hunt et al. examined the medical records of 99 schizophrenia patients in order to 
assess the effect of medication adherence and substance abuse on schizophrenia 
outcomes. A patient was considered to be adherent to their medications if the records 
suggested that he or she regularly took their medications at least 75% of the time. The 
results showed that patients who were both non-adherent and abusing substances had the 
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highest readmission rate per patient (1.45 admissions) and accounted for more than half 
of the hospital admissions in the cohort (58%). The researchers concluded that the 
combination of both medication nonadherence and current substance abuse were 
predictors of hospitalization.157 
 
The studies included in the literature review had several self-reported limitations. The 
most common self-reported limitation was that the measurement technique used to assess 
adherence levels might be inaccurate (29 studies, 57%), with four studies specifically 
citing recall bias and three studies citing desirability bias as a limitation. Another 
commonly stated limitation was that the results from a study could not be generalizable to 
the general population, which was reported as a limitation in 15 of the studies (29%). 
Other limitations cited included the inability to establish temporality, the Hawthorne 
effect due to patient knowledge of observation, possible selection bias, potential coding 
errors, small sample size, and the inability to verify mental illness diagnoses. 
 
IV. Discussion 
a. Summary of evidence 
According to the evidence gathered by the systematic literature review, the consensus of 
previous literature is that alcohol or illicit substance use is significantly associated with 
psychotropic medication nonadherence. Although some of the included studies failed to 
identify a significant correlation between the two factors, these studies accounted for a 
small proportion of the all studies included in the review. As anticipated, no studies found 
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substance abuse to be a predictor of increased medication adherence. A majority of the 
studies observed patient populations with one specific mental illness while a limited 
number more broadly assessed mental illness as a whole. Limited studies observed 
factors in the dual diagnosis population specifically, even though that was the target 
population for the review. No studies in the review observed relapse rates or the impact 
of medication adherence upon substance abuse relapse, which is a vital health outcome of 
substance use disorder treatment. 
 
b. Limitations 
From a review level, there were limitations that require addressing. As in most reviews, 
the quality of studies varied. The studies included patient populations with various 
different characteristics, therefore making it more difficult to compare outcomes study to 
study. Lastly, there was a variation of how substance use was defined from study to 
study. While some studies required patients to have a clinical diagnosis of substance use 
disorder, others only required a self-report of substance use.  
 
At the researcher level, multiple limitations could affect the review’s results. First, only 
one investigator was in charge of identifying, collecting, and assessing the data from 
previous literature, which could result in researcher bias. Another limitation was that non-
English studies were not included; therefore, studies written in foreign languages 
containing relevant data may have been left out of the review. 
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c. Conclusion 
Overall, the literature shows that alcohol and illicit substance use is significantly 
associated with medication nonadherence in the mentally ill population. The literature 
review indicates a lack of research into the effect psychotropic medication nonadherence 
has on the health outcomes of substance use disorder, especially substance use relapse. 
The logical next step for future research would be to observe adherence factors 
specifically in the dual diagnosis population and assess the affect adherence has on 
patient relapse rates. Further data could help interventions tailor treatment to patients 
more effectively, help overcome barriers to treatment, and improve overall health 
outcomes. 
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CHAPTER 3 – METHODS  
I. Study Methodology Overview 
The study utilized a mixed methodology analysis consisting of a cross-sectional patient 
interview, a retrospective facility record supplementation and validation, and a 
prospective follow-up interview. Patients were evaluated within their first week of 
treatment to assess history of substance abuse, mental illness symptom severity, and 
adherence patterns prior to admission. Follow-up interviews were conducted at 1 and 2 
months to reassess mental illness symptoms and adherence. Facility records were 
accessed to cross-reference patient reported data. 
 
II. Data Source 
a. Location 
Participants were recruited from the Salvation Army Harbor Light Center located on the 
North Side in Pittsburgh, Pennsylvania. The Harbor Light Center is a medically-
monitored residential rehabilitation program that provides 90 days of treatment to men 18 
years and older who desire recovery from alcohol and/or other substance abuse problems. 
The services provided to the residents include individual and group counseling, 
coordination of healthcare and behavioral health needs, education of daily living activity 
skills, and referral to community supportive services.195 New admissions to the facility 
(on average, 5 patients per week) receive an intake appointment where an extensive 
clinical interview is conducted on relevant medical, psychiatric, and social 
characteristics. Additionally, a medication interview with the patient is also conducted to 
ascertain relevant pharmacy history. 
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b. Participants 
Newly admitted patients (within the past week) to the Harbor Light Center were recruited 
to participate in the study. Due to the intake policies of the rehabilitation center, patients 
had to be male and at least 18 years of age. Patients eligible for the study further must 
have had a self-reported diagnosis of a substance use disorder and at least one of the 
following mental health diagnoses: (1) major depressive disorder, (2) generalized anxiety 
disorder, (3) bipolar disorder, or (4) schizophrenia. For the purposes of this study, 
patients were excluded from participation if they have been diagnosed with a substance-
induced psychiatric disorder, or if the facility record or patient report is unable to exclude 
this possibility. If a Harbor Light Center counselor stated that a new intake was 
experiencing severe withdrawal symptoms or they were having trouble adjusting to the 
new environment, the researcher postponed the interview until the counselor confirmed 
they were stable enough to participate in the study. The intake personnel were the first to 
make the decision of whether or not a newly admitted patient met the exclusion and 
inclusion criteria, and to make them aware of the ongoing study. This decision was then 
confirmed by the researcher before initiating the primary interview. 
 
III. Data Extraction 
a. Recruitment procedure 
Upon admission to the facility and completion of normal intake procedures, potential 
patients identified to meet inclusion criteria by facility staff were offered the opportunity 
to participate in the study. If the patient had any questions about the process of the study, 
they would be answered initially by the intake personnel before enrollment. The intake 
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facility was given the following study description in order to properly explain the study 
procedures to the patient before they agreed to participate; 
“Duquesne University is currently having a study at Salvation Army and 
is looking for volunteers. We are studying the association between 
substance abuse and taking your medications for depression, bipolar 
disorder, anxiety, or schizophrenia. You will be asked questions about 
your condition once today and again in 1 and 2 months for a follow-up. 
The first interview will take about 30 mins and the follow-up will take 
about 5 mins. Participation in this study will not affect your treatment in 
the Salvation Army program. You will receive $10 for completing the first 
interview and $10 for each follow-up ($30 total).” 
The researcher then contacted the Harbor Light Center staff once per week in order assess 
the number of patient that were interested in potential recruitment for the study. The 
patient recruitment process began in October 2016. 
 
b. Informed consent procedure 
After the patient confirmed they were interested in the study, the researcher conducted a 
face-to-face meeting at the facility in order to explain the study and provide the 
opportunity for informed consent. At this point the participants were given the Consent to 
Participate in a Research Study form (APPENDIX 11) to review and sign. This form, 
along with verbal guidance from the researcher, explained all the information needed in 
order for the participant to provide informed consent. The form lists the investigators 
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involved in the study and their contact information, as well as the contact information for 
the university IRB chair. The participant was informed that any of the investigators may 
be contacted in order to explain the study further or answer any questions about the study 
procedures. The study purpose and participant procedures were then explained in order to 
provide further clarification of the study. The risks and benefits of the study were listed to 
explain to the participant that there are minimal risks associated with the participation but 
are no greater than those encountered in everyday life. The compensation section 
explains that the patient will receive $10 for completing the first in-person interview and 
$10 for each follow-up for a total of $30. The study procedure for maintaining patient 
confidentiality is also explained in the form, stating that their participation in the study 
and any personal information that is provided will be kept confidential at all times and to 
every extent possible. Health Insurance Portability and Accountability Act (HIPAA) 
authorization is explained and states that the patients are aware that they are giving the 
researchers permission to use their personal health information in their medication 
records. All health information procedures in this study are HIPAA compliant, which is 
explained further in the Subject Rights and Ethics section of this chapter. Lastly, the form 
stated that participation in the study would be completely voluntary and that the 
participant has the right to withdraw from the study at any time. As a patient at the 
Harbor Light Center, the participants are under no obligation to participate in the study 
and choosing not to participate or discontinuing participating will in no way affect the 
services provided by the center. Once the researcher established with the participant that 
they clearly understood all aspects of the study, the participants were then required to 
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provide their signature on the Consent to Participate in a Research Study form and orally 
confirm that they understood what they consented to. 
 
c. Primary interview 
After informed consent was obtained, the researcher asked the patient if they wanted to 
begin the study procedures at that same time. If the patient confirmed they wanted to 
begin, the researcher then proceeded with the primary interview portion of the study. If 
the patient requested a delay, a subsequent date and time was arranged. The interview 
served two purposes: (1) measuring agreeance and supplementing data obtained from the 
facility record review, and (2) providing additional evaluation through standardized and 
validated assessment tools to assess medication adherence and psychological symptoms. 
First, the interviewer utilized the Prospective Patient Interview Form (APPENDIX 2) 
and recorded the patient’s responses. This researcher-created instrument was used to 
collect information on patient-reported factors relating to mental illness, substance use 
and relapse, medication history and behaviors, and comorbidities. Next, the Morisky 
Medication Adherence Scale (MMAS-8) (APPENDIX 4) and the Drug Attitude 
Inventory (DAI-10) (APPENDIX 5) were given to the patients to fill out themselves. 
These instruments were used to collect information on the patient’s medication adherence 
tendencies and their attitudes towards their medications. Lastly, depending on the self-
reported mental illness diagnosis, the patients were given a questionnaire in order to 
measure the severity of their mental illness. The Patient Health Questionnaire (PHQ-9) 
(APPENDIX 6) was given to patients with major depressive disorder, the Mood Disorder 
Questionnaire (MDQ) (APPENDIX 7) was given to patients with bipolar disorder, the 
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Generalized Anxiety Disorder Assessment (GAD-7) (APPENDIX 8) was given to 
patients with generalized anxiety disorder, and the Brief Psychiatric Rating Scale (BPRS) 
(APPENDIX 9) was given to patients with schizophrenia. When filling out each form, 
the patients were asked to consider their behavior during the month before entering 
treatment in order to establish a set time period as a reference point. If a patient could not 
fill out the questionnaires on their own, the researcher administered the questions 
verbally and recorded the patient’s responses. After the interview was completed, the 
researcher checked all forms for completeness, thanked the participant and processed the 
reimbursement for their time and participation. The primary interviews took place from 
November 1st, 2016 to June 20th, 2017.  
 
d. Follow-up interview 
Two follow-up interviews were conducted at approximately one and two months post-
primary interview. The follow-up time period was chosen due to the program length, 
rehabilitation goals, and a literature review on relapse rates. Previous studies have found 
that the largest drop in abstinence occurs within the first month (100% to 70%) and then a 
leveling out occurs at three months.196 Before beginning the follow-up interview, the 
researcher reiterated that the same confidentiality procedures from the primary interview 
still applied, and asked if the participant had any questions before continuing. During this 
interview, the interviewer utilized the Longitudinal Follow-up Interview Form 
(APPENDIX 3). Data collected during the follow-up interview included assessment of 
three key areas: (1) relapse to substance use, (2) status of mental illness symptoms, and 
(3) status of medication adherence. Any patients who identified symptoms or presented 
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remarks worrisome for relapse or mental health was offered the opportunity to speak with 
care coordinators at the facility for intervention. If a patient left the program before 
completing both of the follow-up interviews, they were coded as a drop-out and 
information regarding why the patient left was collected from their facility counselors. 
The primary interviews took place from November 29th, 2016 to June 20th, 2017. 
 
e. Facility record review 
After the participant signed the Consent to Participate in a Research Study form and gave 
informed consent, a facility record review was conducted by the co-investigator in order 
to collect additional data on the patients’ risk factors for relapse into substance abuse. 
The facility record data is initially collected by the Harbor Light center staff through an 
intake interview along with other information obtained from the patient’s medical 
records. The data collected through the facility record review included demographics, 
history of substance use and relapse, history of mental illness and treatment, and medical 
comorbidities. The co-investigator extracted data from the facility record using the 
Facility Record Data Collection Form (APPENDIX 1).  
 
IV. Description of Variables 
a. Prospective patient interview form 
The prospective patient interview form is a researcher-designed, 13-item instrument 
consisting of four domains: (1) substance use and relapse, (2) mental illness diagnosis 
and severity, (3) medication history and adherence behavior, and (4) medical 
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comorbidities. The form begins by assessing when the patient checked into Salvation 
Army Harbor Light Center, which was included to determine if the patient was eligible 
for the study and to collect data on how long the patient has been in treatment prior to the 
interview. The substance use and relapse section of the instrument assessed what the 
patient’s primary drug of abuse was, how long the patient has been using said drug, and 
what other illicit drugs the patient had used in their lifetime. The patient was then asked 
to self-report how many times they have relapsed in their substance use and what factors 
they believe have contributed to their relapse(s). Finally, the patient was asked how many 
times they have been in treatment for substance use prior to their current admission to 
Harbor Light.  
 
The mental illness diagnosis and severity section begins by asking if the patient has ever 
been diagnosed with a mental illness by a healthcare professional and if so, what the 
diagnosis was. The patient’s mental illness severity was assessed by asking the patient to 
think back to their mental illness symptoms prior to entering treatment while they were 
still using alcohol or illicit drugs. This was utilized to provide a baseline prior to 
treatment. The patient then self-reported their mental illness severity on a scale of 1 to 10, 
with 1 referring to no symptoms and 10 referring to very severe symptoms. A list of 
symptoms commonly related to depression, bipolar disorder, generalized anxiety, and 
schizophrenia was included in order to help the patient assess the symptoms that were 
particularly relevant.  
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The medication history and adherence behavior section begins by asking the patient if 
they have received any medication for their mental illness from a healthcare professional 
and if so, what medications they currently were taking and what medications have they 
previously taken. The patient is then asked to self-report their psychotropic medication 
adherence both a month before coming to treatment while still using alcohol and illicit 
substance and in their general lifetime. This adherence measure was scored on a scale of 
1 to 10, with 1 referring to taking no doses and 10 referring to taking all doses as 
prescribed. If the patient was unsure of what the term adherence means, the researcher 
helped explain it to them in more detailed language. The patient was then asked what 
factors they believe have contributed to them not properly taking their medications.  
 
Lastly, the patients’ comorbidities were assessed by asking if they have ever been 
diagnosed with any other chronic medical condition by a healthcare professional, such as 
hepatitis C, diabetes, or high blood pressure and if so, what the diagnosis was. The 
patient was also asked if they are currently taking any prescribed medications for these 
comorbidities. 
 
b. Morisky Medication Adherence Scale (MMAS-8) 
The Morisky Medication Adherence Scale (MMAS-8), a multidimensional self-reported 
8-item measure, was utilized to assess the patients’ psychotropic medication adherence. 
The MMAS-8 seeks to measure adherence by identifying the underlying factors that lead 
to nonadherence such as forgetfulness, side effects, decreasing symptom severity, and 
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complexity of the patient’s medical regimen.197-199 Each item measures a specific 
adherence behavior and cannot be used individually as a determinant of adherence. The 
first seven items of the MMAS-8 are dichotomous responses requiring a yes or no 
response and the last item is a five-point Likert-scale. The items utilize reverse wording 
resulting in both positive and negative questioning about adherence behaviors in order to 
avoid desirability bias or patients giving only positive yes responses.200 The MMAS-8 
scoring system is copyright protected and available for licensing from the originator. A 
patient’s final score can be categorized low adherence, medium adherence, or high 
adherence. As for psychometric properties, a 93% sensitivity and 53% specificity was 
reported while validating the tool in a cohort of low income patients treated for 
hypertension in an out-patient setting. The same study also reported a Cronbach’s alpha 
value of 0.83, which is above the acceptance threshold of acceptability.200 The MMAS-8 
was chosen as the adherence measurement for the study due to its popularity, common 
usage in various clinical settings, widespread use in different diseases, populations, and 
countries, high level of concordance with pharmacy fill data and electronic adherence 
monitoring devices, and low response burden due to its conciseness. 201 The current study 
utilized the general MMAS-8, although other condition and medication-specific forms of 
the measure are available. 
 
c. Drug Attitude Inventory (DAI-10) 
The Drug Attitude Inventory (DAI-10) (APPENDIX 5) was utilized to measure patient 
attitudes and beliefs in regard to their prescribed psychotropic medications that may 
contribute to their adherence levels. The DAI is a 10-item, true/false, self-reported 
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measure that analyzes a patient’s subjective feelings towards medication. For example, 
the DAI assesses if a patient believes that it is unnatural to take medication, if the good 
things about medication outweigh the bad, or if they stop taking medication once they 
feel better. In regard to scoring the DAI, questions that reflect a positive attitude towards 
medication are scored as +1 if the patient answers true and -1 if the patient answers false, 
whereas questions that reflect a negative attitude are scored as -1 if answered true and +1 
if answered false. The total scoring of the DAI ranges from -10 to +10 with a total score 
greater than 0 representing a positive attitude towards medications, a total score less than 
zero representing a negative attitude towards medications and a total score of 0 
representing a neutral attitude towards medication.202 Previous research has shown that 
the reliability and validity of the DAI is similar to or greater than other common 
medication adherence screening instruments when used within the mentally ill 
population.203 The DAI was used in the study due to its ease of administration and low 
response burden.  
 
d. Condition specific measures 
i. Patient Health Questionnaire (PHQ-9) 
The Patient Health Questionnaire (PHQ-9) (APPENDIX 6) is a self-reported, 9-item 
instrument designed to screen, diagnose, monitor, and measure the severity of major 
depressive disorder (MDD). The PHQ-9, which was generated from the full 3-page PHQ 
questionnaire, incorporates both DSM-IV diagnostic criteria along with other common 
symptoms of depression. As stated, the PHQ-9 can be used as a diagnosis tool as well as 
a severity measure. For a patient to be diagnosed with MDD, he or she must answer 
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“More than half the days” or “Nearly every day” to question 1 and 2, must have 5 or 
more of the symptoms present on more than half the days, and must have not checked 
“not difficult at all” for question 10. When being used as a severity measure, the PHQ-9 
score ranges from 0 to 27. A score of 5 represents mild, 10 represents moderate, 15 
represents moderately severe, and 20 represents severe depression.204 The PHQ-9 has 
been shown to have strong psychometric properties, with an internal reliability of 89% 
and a test-retest reliability of 84%. The PHQ-9 has also been validated for criterion 
validity and construct validity within the mental illness population.205 The PHQ-9 was 
chosen to be used in the study due to its low response burden, simple scoring and 
common usage in clinical settings.   
 
ii. Generalized Anxiety Disorder Assessment (GAD-7) 
The Generalized Anxiety Disorder Assessment (GAD-7) (APPENDIX 8) is a 7-item 
self-reported screening instrument for patients with generalized anxiety disorder. The 
scale consists of 7 items related to the DSM-IV symptom criteria for GAD. The patients 
reported how often they have experienced these symptoms over the past two weeks with 
the options of selecting “Not at all”, “Several days”, “Over half the days”, and “Nearly 
every day”. In order to score the GAD-7, each answer is given a weighted score (not at 
all = 1, several days = 2, over half the days = 3, nearly every day = 4) and the scores are 
added together to get a total score. Similar to the PHQ-9, the GAD-7 can be used as both 
a diagnostic tool and a symptom severity measure. A score of 10 or more can be 
interpreted as a probable diagnosis of GAD, which can be confirmed by further 
psychiatric evaluation. As for severity, a score of 5 refers to mild anxiety, 10 refers to 
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moderate anxiety, and 15 refers to severe anxiety.206 In a study conducted by Spitzer et 
al., the psychometric properties of the GAD-7 were measured in a population of 2,740 
adult patients in 15 primary care clinics. The researchers found a high internal 
consistency of 92% and a test-retest reliability of 83%. In addition, the researchers also 
concluded the GAD-7 had good criterion, construct, factorial, and procedural validity.206 
The GAD-7 was chosen for this study due to its conciseness, ease of scoring, and strong 
psychometric properties. While the GAD-7 was intended for screening, the study used it 
as a measurement for severity. The GAD-7 has been established in previous literature as 
a valid and efficient tool for assessing GAD severity in clinical practice and research.206 
 
iii. Mood Disorder Questionnaire (MDQ) 
The Mood Disorder Questionnaire (MDQ) (APPENDIX 7) is a 15-item self-reported 
screening instrument for patients with bipolar disorder. The instrument consists of five 
questions, of which the first lists 13 items related to the DSM-IV symptom criteria for 
bipolar disorder. The MDQ then assess if these symptoms occurred in the same period, 
the impact of the symptoms on the patient’s life, whether the patient has a family history 
of bipolar disorder, and if the patient has been previously diagnosed with bipolar 
disorder. In order to receive a positive screening for bipolar disorder, the patient must 
exhibit 7 of the 13 symptoms listed in question 1, must have experienced more than one 
of these symptoms at the same time, and must report these symptoms have resulted in 
either moderate or serious problems in their life.207 In a study conducted by Hirschfeld et 
al., the psychometric properties of the MDQ were measured using a cohort of 198 
patients at five outpatient psychiatric clinics. The results showed the MDQ has a high 
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internal consistency of 90%. The researchers also found that the MDQ has a good 
sensitivity (0.73; 95% CI: 0.65- 0.81) and a good specificity (0.90; 95% CI: 0.84-0.96).208 
The MDQ was chosen for this study due to its timely and accurate evaluation of bipolar 
disorder. Similarly, to the GAD-7, the MDQ was intended for screening but the study 
used it as a measurement for severity which has been reported in previous literature.209  
 
iv. Brief Psychiatric Rating Scale (BPRS) 
The Brief Psychiatric Rating Scale (BPRS) (APPENDIX 9) is a widely utilized, 18-item 
instrument used to assess the positive, negative and affective symptoms in patients with 
psychotic disorders, especially schizophrenia. Each item of the instrument gives a 
description of a specific symptom related to psychotic disorders and the patient assigns a 
number to each symptom that correlates with their self-reported severity, ranging from 1 
(not present) to 7 (extremely severe). While there is no established total scoring criteria 
for the BPRS, the scores of the 18 items can be added together and compared to other 
patients or measured for change over time.210 While there is a lack of research into the 
BPRS’s psychometric properties, one study conducted by Anderson et al. found that the 
instrument has both adequate reliability (78%) and validity (66%) in the psychotic 
population.211 The BPRS was chosen for this study due to its wide use in the psychiatric 
field in order to assess patients with schizophrenia.  
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e. Longitudinal follow-up interview form  
The Longitudinal Follow-up Interview Form (APPENDIX 3) is a researcher-designed, 6-
item instrument consisting of three domains: (1) substance use relapse, (2) mental illness 
symptom severity, and (3) psychotropic medication adherence. The form begins by 
asking the patient if he resumed the use of any alcohol or drugs since the last interview. If 
the patients answered yes, the interviewer assessed when the relapse occurred and if the 
patient has sought help. Then the patient was asked to report how their mental illness 
symptoms have changed since the last interview, with the options of “no current 
symptoms,” “symptoms decreased,” “symptoms increased,” and “symptoms remained the 
same.” Similar to the Prospective Patient Interview Form, a list of symptoms commonly 
related to depression, bipolar disorder, generalized anxiety, and schizophrenia is included 
in order to help the patient assess their symptom severity level. Lastly, the patients were 
asked to assess their adherence levels since the last interview on a scale of 1 to 10, with 1 
referring to taking no doses and 10 referring to taking all doses as prescribed. If the 
patient has not taken their medications as prescribed, they were asked what factors they 
believed contributed to the nonadherence.  
 
f. Facility record data collection form 
The Facility Record Data Collection Form (APPENDIX 1) is a 19-item form created by 
the researchers to collect information on newly admitted patients from the facility intake 
form. The form consists of four sections, which are patient demographics, history of 
substance use and relapse, history of mental illness treatment and adherence, and medical 
comorbidities. The data collected on patient demographic and social characteristics 
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include age, race/ethnicity, employment status, income level, education background, 
housing situation, and family support. The data collected on the patient’s substance use 
and relapse history include the patient’s primary substance of use and other substances 
used, age of first use, length of use, longest time clean, and number of admissions at 
Harbor Light Center and other rehabilitation programs. Other rehabilitation program 
stays were defined as any time a patient received inpatient or outpatient treatment for 
their SUD outside of the Harbor Light Center. The data collected on patient mental 
illness history include both patient-reported and medically-assigned mental illness 
diagnosis, age of diagnosis, severity, pharmacological or non-pharmacological treatment 
both current and previous, and medication adherence levels. The intake faculty 
determines the patient’s mental illness severity level by assessing their signs of withdraw, 
the presence of post-acute withdraw syndrome, visible SUD symptoms, psychological 
and emotional drug cravings, mood stability, and presence of auditory or visual 
hallucinations. Patient adherence levels are determined through the intake faculty 
assessing the patient’s external and internal motivation. Lastly, the patient’s other 
medical comorbidity diagnoses are assessed and reported.  
 
V. Data and Statistical Analysis 
a. Research objective 1 
The first objective of the study was to identify personal, social and clinical histories for 
patients with substance use disorder and either major depressive disorder, bipolar 
disorder, schizophrenia or generalized anxiety disorder. Data for this objective was 
collected from both the primary interview and the facility records. This objective was 
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accomplished through a descriptive analysis of the following variables: age, race 
(Caucasian and African American), employment status (unemployed, employed, 
disabled), socioeconomic status (monthly income level), educational background (less 
than high school, high school, more than high school), housing situation (homeless, living 
with family, other), number of incarcerations, primary substance of use, number of 
previous relapses, number of previous treatment stays, number of previous times at 
Harbor Light, age of first substance use, mental illness diagnosis, mental illness severity 
level, number of other medical comorbidities, and number of psychotropic medications 
prescribed. The variables were broken down into the categories listed above in order to 
make a proper analysis and compare the information. The data for this analysis was 
primarily gathered through the facility data record collection with some supplementation 
from data collected through the primary interviews. Data gathered from the facility data 
record collection included age, race, employment status, socioeconomic status, 
educational background, housing situation, number of incarcerations, number of previous 
times at Harbor Light, and age of first substance use. Data collected through primary 
interviews included primary substance of use, number of pervious relapses, number of 
previous treatment stays, mental illness diagnosis, number of other medical 
comorbidities, and number of psychotropic medications prescribed. Results were reported 
using frequencies, means with standard deviations, and medians with ranges.  
 
b. Research objective 2 
The second objective of the study was to identify discrepancies between patient self-
reported data versus facility record data in regard to mental illness traits, substance abuse 
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history, and psychotropic medication. This objective was accomplished through two 
analyses of the following variables: primary substance of use, mental illness diagnosis, 
number of mental illness comorbidities, number of psychotropic medications prescribed, 
number of other comorbid diagnoses, and number of previous treatment stays. These 
variables were chosen for this analysis due to them being collected at both the primary 
patient interview and the facility data record collection. The above variables also play a 
vital role in study’s other statistical analysis, therefore the accuracy of the patient self-
reported should be confirmed. Cohen’s kappa coefficient was utilized to determine 
agreement between self-reported and facility record data. This statistical analysis was 
chosen over a simple percent agreement calculation due it being a more robust measure 
that takes into account agreement occurring by chance.212  
 
c. Research objective 3 
The third objective was to investigate the specific role of medication adherence and 
barriers to use for psychotropic medications upon substance abuse relapse. Data for this 
objective was collected from both the primary interview and the facility records. This 
objective was completed through five separate analyses. First, patient demographic 
characteristics were stratified by self-reported adherence rates, MMAS-8 total score, and 
number of self-reported relapses. The variables observed in this analysis included age 
(18-29, 30-39, 40-49, 50+), race/ethnicity, employment status, socioeconomic status, 
education background, housing situation prior to entry, and number of incarcerations (0, 
1, 2, 3+). The mean and standard deviation of adherence scores and relapses 
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corresponding with each variable were reported then mean scores were assessed for 
significant differences.  
 
The patients’ substance abuse characteristics were then stratified by self-reported 
adherence rates, MMAS-8 total score, and number of relapses. Substance abuse 
characteristics included the variables of primary substance of use (heroin, alcohol, crack 
cocaine, other), number of distinct drugs used (≤3, 4-9, 10+), and length of use (less than 
10 years, 10 to 29 years, 30+ years). If there was a discrepancy between patient reported 
data and facility records, patient reported data was used in the analysis. 
 
The patients’ health related characteristics were then compared according to self-reported 
adherence rates, MMAS-8 total score, and number of relapses. The mental illness 
characteristics included in this analysis were mental illness diagnosis (MDD, GAD, 
bipolar disorder, schizophrenia, more than 1 mental illness), self-reported mental illness 
severity level (1-6, 7-9, 10), number of psychotropic medications prescribed (1-2, 3-4, 
5+), presence of more than one mental illness (yes, no), PHQ-9 score (not present, mild, 
moderate, moderately severe, severe), MDQ score (negative, positive), and GAD-7 (not 
present, mild, moderate, severe). The BPRS scores were excluded from this analysis due 
to only two patients having schizophrenia and both patients received similar scores for 
severity level. Similar to the substance abuse characteristics, if there was a discrepancy 
between patient reported data and facility records, patient reported data was used in the 
analysis. 
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The patients’ attitudes towards medications were then analyzed by stratifying the DAI 
results by self-reported adherence rate, MMAS-8 total score, and number of relapses. The 
total scores of the DAI were first compared according to adherence and relapses then 
each question was broken down individually.  
 
Patients’ adherence scores were correlated with the self-reported number of relapses in 
order to assess the overall relationship between psychotropic medication adherence and 
substance use relapse. Pearson’s correlation coefficient was utilized for this statistical 
analysis. The four adherence measurements included were the MMAS-8 total score, 
MMAS-8 intentional score, MMAS-8 unintentional score, and self-report adherence rate. 
 
A multivariable logistic regression model was then created in order to assess the direct 
impact psychotropic medication adherence has on relapse frequency. Patient 
characteristics that were hypothesized to be a predictor of relapse were included in the 
model. Said characteristics were MMAS-8 total score, self-reported mental illness 
symptom severity level, mental illness type, length of substance use and DAI total score. 
All variables except for mental illness type were classified as continuous variables. 
Mental illness type was classified as a nominal variable composed of the following 
groups: MDD, GAD, Bipolar, Schizophrenia, 2+.  
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In regard to statistical analyses, t-test and ANOVAs were utilized for continuous 
variables and chi square tests for categorical variables. When t-tests were used, Levene’s 
test for equality of variance was utilized to assess variance within the data. For ANOVAs, 
a test of homogeneity of variance was run to assess variance within the data. If there was 
no significant variance, Tukey’s post hoc was then used to determine between which 
variables the significant difference had occurred. If significant variance was present then 
the Dunnett T3 statistic was used. As stated, Pearson’s correlation coefficient was utilized 
for the correlation analysis. An a priori p-value of <0.05 was considered statistically 
significant for all statistical assessments and effect sizes will be reported when 
applicable, using Cohen’s d and odds ratio with a 95% confidence interval.  
 
d. Research objective 4 
The fourth and final research objective was to assess follow-up changes in mental illness 
severity and medication adherence in dual diagnosis patients enrolled in a substance 
abuse rehabilitation program. Data for this objective was collected from both the primary 
interview and the follow-up interviews. This was accomplished through three analyses. 
First, the frequency and percentage of patients was reported according to which interview 
they completed (primary interview only, 1st follow-up, 2nd follow-up). Second, patient 
characteristics including age, MMAS-8 total score, MMAS-8 intentional score, MMAS-8 
unintentional score, self-reported adherence rate, mental illness type, mental illness 
symptom severity, substance of choice, DAI-10 total score, receiving income, and 
housing situation were stratified according to follow-up interviews completed. Lastly, 
changes in patients’ self-reported adherence from interview to interview were analyzed in 
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order to assess for significant change in adherence over time while enrolled in the 
rehabilitation program. The results in this analysis were reported in mean difference.  
 
e.  Missing data 
Missing data was not adjusted for in the statistical analysis of the study results. Due to the 
methodological design of the study, the researchers concluded that missing data would 
have no impact on the results of the study. The interviewer checked each form for 
completeness during the primary interviews and follow-up interviews before the 
interview concluded. If the patient missed any question, they were simply asked to 
complete it before leaving, therefore there was no missing data from the primary data 
collection step of the study. Patients who dropped out of the study were not considered 
missing data. They were moved to the drop-out group of the study sample and analyzed 
from that perspective. As for the facility data, only one patient had missing data for their 
mental illness diagnosis. The patient self-reported a MDD diagnosis and the facility data 
confirmed that the patient was prescribed the SSRI Prozac® and the antidepressant 
Remeron®. Therefore, the researchers safely assumed that the patient was diagnosed with 
MDD. Two patients had not reported their previous living status during their intake 
interview but this played an insignificant role in the overall analysis. There were no other 
cases of missing data prevalent in the data included in the statistical analysis.  
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VI. Data Capture 
During the primary and follow-up patient interviews, information was collected using 
paper data collection forms and was then transferred to a SPSS datafile. Data collected 
through the facility record reviews were entered directly into an excel spreadsheet. The 
Morisky Widget (MMAS Research LLC) was utilized in order to score and record the 
results of the MMAS-8. Permission for use and a license agreement was obtained from 
MMAS Research LLC. SPSS Statistics 22 (IBM; Armonk, NY) was utilized for all 
statistical comparisons and modeling. 
 
VII. Subject Rights and Ethics 
Due to the vulnerable nature of the study participants, enhanced care was given to 
research ethics and subject rights. The study underwent and received a full board 
approval by the Duquesne University Institutional Review Board, and the thesis 
committee included a faculty member with specialized expertise in psychology, addiction 
and research ethics for supervision. Before beginning any data collection, the researcher 
confirmed that the participants fully understood the confidentiality protocol, their right to 
withdraw, and HIPAA authorization, using both verbal and written explanations. All 
health information procedures in the study were HIPAA compliant and no protected 
health information (PHI) was recorded in any data collection procedure. Patient names 
never appeared on any research instrument and their responses were only reported 
through statistical data summaries. Each patient was given a study ID number in order to 
keep their identity anonymous. A study ID log that matched each ID number to their 
corresponding patient’s name was kept in a Harbor Light Center facility member’s office 
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and was only removed in order to conduct the patient record review process. All other 
patient data collected throughout the study were kept confidential at all times and were 
protected to every extent possible. 
 
After completing patient interviews, the data collected was uploaded onto a password 
protected computer located in the graduate student office located on Duquesne 
University’s campus. The researchers had the sole access to the protected data. All 
materials with personal or health information will be maintained for three years. 
Electronic data will be manually deleted from the computer’s hard drive and all physical 
material will be shredded by the researchers at the completion of the study.  
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CHAPTER 4 – RESULTS  
 
I. Objective 1 
Identify personal, social, and clinical history for patients with substance use disorder and 
either major depressive disorder, bipolar disorder, schizophrenia, or generalized anxiety 
disorder 
a. Demographics 
The final study sample consisted of 38 patients. The study data collection period took 
place from November 1st, 2016 to June 20th, 2017. A majority of the patients were white 
(n=27, 71.1%) and the rest were African American. The mean age of the patients was 
40.8±11.4 years old. A total of 32 (84.2%) patients were unemployed and 7 (18.4%) 
patients were receiving any form of income before entering treatment, with an 
approximate monthly income level of $145.08 which includes those receiving no income. 
Patients’ education level was somewhat evenly distributed, with 15 patients (39.5%) 
having less than a high school education, 15 (39.5%) having a high school degree, and 8 
(21.1%) having more than a high school education. The median number of incarcerations 
was 1 with a range of 0 to 4. A majority of the patients were homeless before entering 
treatment (n=30, 78.9%). The frequencies and percentages of patient demographics are 
outlined in Table 2.   
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Table 2:  Demographic Characteristics  
  
Demographic Characteristics 
n (%) unless specified otherwise 
Study Sample 
(n=38) 
Age (mean, st dev) 40.8 (11.4) 
Race/ethnicity: 
     Caucasian 
     African American 
 
27 (71.1) 
11 (28.9) 
Employment status prior to treatment: 
     Unemployed 
     Disabled 
     Employed 
 
32 (84.2) 
4 (10.5) 
2 (5.3) 
Approximate monthly income level ($) prior to treatment (mean, st dev) 145.08 (318.65) 
Receiving any income prior to treatment: 
     Yes 
     No 
 
7 (18.4) 
31 (81.6) 
Educational background: 
     Less than high school 
     High school 
     More than high school 
 
15 (39.5) 
15 (39.5) 
8 (21.1) 
Housing situation prior to treatment:  
     Homeless 
     Living with family 
     Other 
     Missing 
 
30 (78.9) 
2 (5.2) 
4 (10.5) 
2 (5.3) 
# of incarcerations 
     Mean, st dev 
     Median, range 
 
1.2 (1.2) 
1.0 (0-4) 
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b. Substance use characteristics 
In terms of substance use characteristics, heroin was the most common primary drug of 
use among patients (n=19, 50%), followed by alcohol (n=12, 31.6%), and crack cocaine 
(n=4, 10.5%). Other substances used by patients included marijuana, methamphetamines, 
cocaine, benzodiazepines, hallucinogens, opiates, buprenorphine/naloxone, 
amphetamines, Robitussin®, and research chemicals. The average number of substances 
used was 5.4 and the average length of substance use was 20.3 years, with the average 
age of first substance use being 13.1 years old. The average number of rehabilitation 
treatment center stays before entering Harbor Light was 6.1 stays. Lastly, the average 
number of previous relapses was 9.7 among the patient population. The frequencies and 
percentages of patient substance use characteristics are outlined in Table 3.  
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Table 3: Substance Use Characteristics  
  
Substance Use Characteristics 
n (%) unless specified otherwise 
Study Sample (n=38) 
Primary substance of use: 
     Heroin 
     Alcohol 
     Crack cocaine 
     Alcohol/cocaine 
     Marijuana 
     Methamphetamines 
 
19 (50.0) 
12 (31.6) 
4 (10.5) 
1 (2.6) 
1 (2.6) 
1 (2.6) 
# of distinct substances used 
     Mean, st dev 
     Median, range 
 
5.4 (2.8) 
4 (1-10) 
# of previous relapses 
     Mean, st dev 
     Median, range 
 
9.7 (14.1) 
6 (0-75) 
# of previous treatment stays 
     Mean, st dev 
     Median, range 
 
6.1 (6.0) 
4 (0-25) 
Length of substance use (mean, st dev) 20.3 (13.7) 
Age of first use (mean, st dev) 13.1 (3.0) 
  90 
c. Health-related characteristics  
In regard to health characteristics, half of the patients (n=19, 50%) had two or more 
mental illness diagnoses. The most common mental illness was the combination between 
MDD and GAD (n=9, 23.7%), followed by MDD alone (n=7, 18.4%), and bipolar 
disorder (n=6, 15.8%). Four patients had a combination of MDD, GAD, and bipolar 
disorder. This combination of mental illness was the only instance of patients having 
three or more comorbidities. On a scale from 1 to 10, the average self-reported mental 
illness severity level was 8.39±1.93. Patients were prescribed an average of 2.3 
psychotropic medications and the number of other comorbid diagnoses was 2.3. The 
frequencies/percentages of patient health-related characteristics are outlined in Table 4.  
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Table 4: Health-related Characteristics  
  
Health-related characteristics 
n (%) unless specified otherwise 
Study Sample (n=38) 
Co-morbid mental illness: 
     Major depressive disorder (MDD) 
     Generalized anxiety disorder (GAD) 
     Bipolar 
     Schizophrenia 
     Comorbidity (2+ conditions) 
          MDD and GAD 
          Bipolar and Schizophrenia 
          MDD, GAD, and Bipolar 
          GAD and Bipolar 
          MDD and Bipolar 
 
7 (18.4) 
4 (10.5) 
6 (15.8) 
2 (5.4) 
19 (50.0) 
     9 (23.7) 
     2 (5.4) 
     4 (10.5) 
     2 (5.3) 
     2 (5.3) 
Self-reported mental illness severity 
     Mean, st dev 
     Median, range  
 
8.39 (1.93) 
9.0 (1-10) 
# of other comorbid diagnoses 
     Mean, st dev 
     Median, range  
 
2.3 (1.8) 
1 (0-3) 
# of psychotropic medications prescribed 
     Mean, st dev 
     Median, range  
 
2.3 (1.40) 
2 (0-6) 
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II. Objective 2 
Measure agreeance between patient self-report versus facility record history for mental 
illness, substance abuse, and psychotropic medication 
a. Patient-report and facility record comparison 
Results from the patient interviews were compared to the facility medical records in order 
to identify discrepancies and to test the agreeance of the patient self-reported data. 
Cohen’s kappa, which measures the extent of agreement among data collected by two 
different collectors, showed a significant agreeance in the reporting of primary substance 
of use (κ=0.753, p<.001), mental illness diagnosis (κ=0.434, p<.001), number of mental 
illness comorbidities (κ=0.257, p=0.008), and number of psychotropic medications 
prescribed (κ=0.094, p<.001). Cohen’s kappa showed an insignificant agreeance between 
patient self-report and facility records for number of other comorbid diagnoses (κ=0.094, 
p=0.176) and number of previous treatment stays (κ=0.107, p=0.05). Patients reported 
less comorbid diagnoses (median 1.0 vs 2.0) and more previous treatment stays (median 
4.0 vs 3.0) when compared to facility records. The results of the patient-report and 
facility record comparison are outlined in Table 5. 
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Table 5: Patient Report vs Facility Record Data 
Variables 
Patient interview 
N (%) 
Medical record 
N (%) 
Cohen’s κ p-value 
Primary substance of use: 
     Alcohol 
     Alcohol and cocaine 
     Crack cocaine 
     Heroin 
     Heroin and opiates 
     Marijuana 
     Methamphetamine  
     Opiates 
 
12 (31.6) 
1 (2.6) 
4 (10.5) 
17 (44.7) 
1 (2.6) 
1 (2.6) 
1 (2.6) 
1 (2.6) 
 
17 (44.7) 
0 (0.0) 
1 (2.6) 
19 (50.0) 
0 (0.0) 
0 (0.0) 
1 (2.6) 
0 (0.0) 
 
 
 
 
0.753 
 
 
 
 
<.001* 
Mental illness diagnosis 
     GAD 
     GAD and Bipolar 
     GAD, Bipolar, and MDD 
     GAD and MDD 
     Bipolar 
     Bipolar and MDD 
     Bipolar, MDD and Schizophrenia 
     Bipolar and Schizophrenia 
     MDD 
     MDD and Schizophrenia 
     Schizophrenia  
     Missing      
 
4 (10.5) 
2 (5.3) 
4 (10.5) 
9 (23.7) 
6 (15.8) 
2 (5.3) 
0 (0.0) 
2 (5.3) 
7 (18.4) 
0 (0.0) 
2 (5.3) 
0 (0.0) 
 
4 (10.5) 
0 (0.00 
7 (18.4) 
10 (26.3) 
6 (15.8) 
4 (10.5) 
1 (2.6) 
1 (2.6) 
2 (5.3) 
1 (2.6) 
1 (2.6) 
1 (2.6) 
 
 
 
 
 
 
0.434 
 
 
 
 
 
 
<.001* 
# of mental illness comorbidities (median, range) 2.0 (1-5) 2.0 (1-4) 0.257 <.001* 
# of psychotropic medications prescribed (median, range) 2.0 (0-6) 3.0 (1-7) 0.240 <.001* 
# of other comorbid diagnoses (median, range) 1.0 (0-3) 2.0 (0-9) 0.094 0.176 
# of previous treatment stays (median, range) 4.0 (0-25) 3.0 (0-8) 0.107 0.052 
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III. Objective 3 
Investigate the specific role of medication adherence and barriers to use for psychotropic 
medications upon substance abuse relapse 
 
a. Measurement scores breakdown 
i. MMAS-8 
The Morisky Medication Adherence Scale (MMAS-8) was utilized to measure patient’s 
adherence. The patients’ average score was 3.5±2.0, considered low adherence. A total of 
33 (86.6%) of patients had low adherence, 4 (10.5%) had medium adherence, and only 1 
patient (2.6%) had high adherence. Patients received similar average scores for both 
intentional and unintentional adherence. The results for each individual question of the 
MMAS-8 is shown in Table 6.  
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Table 6: MMAS-8 Breakdown 
MMAS-8 Question 
Response  
N (%) 
Total score (mean, st dev) 3.5 (2.0) 
1. Do you sometimes forget to take your pills?   
     Yes 
 
30 (78.9) 
2. People sometimes miss taking their medications for reasons other than 
forgetting. Thinking over the past two weeks, were there any days when you did 
not take your medicine?   
     Yes 
 
 
 
22 (57.9) 
3. Have you ever cut back or stopped taking your medication without telling your 
doctor, because you felt worse when you took it?   
     Yes 
 
 
23 (60.5) 
4. When you travel or leave home, do you sometimes forget to bring along your 
medication?   
     Yes 
 
 
27 (71.1) 
5. Did you take your medicine yesterday?   
     Yes 
 
30 (78.9) 
6. When you feel like your symptoms are under control, do you sometimes stop 
taking your medicine?   
     Yes 
 
 
23 (60.5) 
7. Taking medication every day is a real inconvenience for some people. Do you 
ever feel hassled about sticking to your treatment plan?   
     Yes 
 
 
20 (52.6) 
8. How often do you have difficulty remembering to take all your medications?   
     Never 
     Almost Never 
     Sometimes 
     Frequently  
     Always 
 
1 (2.6) 
14 (36.8) 
15 (39.5) 
6 (15.8) 
2 (5.3) 
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ii. DAI-10 
The Drug Attitude Inventory (DAI-10) was given to the patients in order measure patient 
attitudes and beliefs in regard to their prescribed psychotropic medications that may 
contribute to their adherence levels. The cutoff point for the DAI is 0; therefore, a 
negative score reflects a negative attitude, a score of 0 reflects a neutral attitude, and a 
positive score reflects a positive attitude. The mean total score was 5.4±3.0 which reflects 
a positive attitude towards medications. Almost all of the patients received a score above 
0 (n=34, 98.5%), while three patients (7.9%) scored 0 and only one patient (2.6%) scored 
below zero. The results for each individual question of the DAI-10 along with the total 
scoring is shown in Table 7.  
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Table 7: DAI-10 Breakdown 
Drug Attitude Inventory (DAI-10) 
Response  
N (%) 
Total score (mean, st dev) 5.4 (3.0) 
Total score rating 
     Negative attitude (<0) 
     Neutral (0) 
     Positive attitude (>0) 
 
1 (2.6) 
3 (7.9) 
34 (98.5) 
1. For me, the good things about medication outweigh the bad 
     True 
     False 
 
34 (89.5) 
4 (10.5) 
2. I feel strange, “doped up”, on medication 
     True 
     False 
 
12 (31.6) 
26 (68.4) 
3. I take medications of my own free choice 
     True 
     False 
 
33 (86.8) 
5 (13.2) 
4. Medications make me feel more relaxed 
     True 
     False 
 
31 (81.6) 
7 (18.4) 
5. Medication makes me feel tired and sluggish 
     True 
     False 
 
19 (50.0) 
19 (50.0) 
6. I take medication only when I feel ill 
     True 
     False 
 
8 (21.1) 
30 (78.8) 
7. I feel more normal on medication 
     True 
     False 
 
32 (84.2) 
6 (15.8) 
8. It is unnatural for my mind and body to be controlled by medications 
     True 
     False 
 
13 (34.2) 
25 (65.8) 
9. My thoughts are clearer on medication 
     True 
     False 
 
27 (71.1) 
11 (28.9) 
10. Taking medication will prevent me from having a breakdown 
     True 
     False 
 
27 (71.1) 
11 (28.9) 
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b. Results stratified by adherence and relapse  
i. Patients characteristics 
Patient characteristics including age (18-29, 30-39, 40-49, 50+), race/ethnicity 
(Caucasian, African American), employment status (unemployed, employed, disabled), 
receiving income (yes, no), educational background (less than high school, high school, 
more than high school), housing situation (homeless, living with family, other), 
incarcerations (0, 1, 2, 3+), and number of comorbid health conditions (0, 1-2, 3-4, 5+) 
were stratified according to total MMAS-8 score, self-reported adherence on a scale from 
1-10, and self-reported relapse rate. The results showed that the group of patients who 
were receiving income prior to admission had significantly higher mean relapse rates 
compared to the group of patients who were not receiving income (16.9 vs 8.1, p=0.02). 
The results of this analysis are shown in Table 8.  
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Table 8: Patients Characteristics Stratified by Adherence and Relapse 
Demographic Characteristic 
Adherence  
(MMAS-8 score; 
mean, st dev) 
Adherence  
(self-report; 
mean, st dev) 
Relapses 
(self-report; mean, 
st dev) 
Age  
     18-29 
     30-39 
     40-49 
     50+ 
 
3.6 (2.5) 
3.9 (1.5) 
3.9 (2.4) 
2.4 (1.2) 
 
3.3 (4.6) 
3.6 (3.3) 
2.9 (3.2) 
2.1 (3.3) 
 
6.3 (3.1) 
5.7 (7.3) 
11.5 (13.7) 
15.5 (24.2) 
Race/ethnicity: 
     Caucasian 
     African American 
 
3.5 (1.9) 
3.7 (2.1) 
 
2.9 (3.4) 
3.6 (3.4) 
 
11.7 (16.3) 
4.8 (3.2) 
Employment status: 
     Unemployed 
     Disabled 
     Employed 
 
3.5 (1.9) 
5.2 (1.9) 
1.5 (0.0) 
 
2.8 (3.2) 
5.5 (5.2) 
2.0 (00) 
 
8.9 (13.5) 
7.3 (2.5) 
29.0 (29.7) 
Receiving income 
     Yes 
     No 
 
4.1 (2.6) 
3.4 (1.8) 
 
2.7 (3.0) 
4.6 (4.8) 
 
16.85 (25.7)* 
8.1 (9.9)* 
Educational background: 
     Less than high school 
     High school 
     More than high school 
 
4.2 (1.9) 
3.5 (1.8) 
2.5 (2.1) 
 
3.1 (3.8) 
3.7 (3.6) 
1.6 (1.1) 
 
8.5 (12.0) 
7.4 (5.6) 
16.1 (25.3) 
Housing situation  
     Homeless 
     Living with family 
     Other 
 
3.5 (2.0) 
2.4 (0.2) 
3.9 (2.7) 
 
2.7 (3.1) 
2.0 (1.4) 
5.0 (4.7) 
 
10.1 (15.7) 
5.5 (0.7) 
11.0 (6.2) 
Incarcerations  
     0 
     1 
     2 
     3+ 
 
3.2 (2.1) 
4.0 (2.1) 
4.3 (1.6) 
2.3 (1.6) 
 
2.0 (2.5) 
3.6 (4.1) 
3.5 (3.0) 
4.2 (4.5) 
 
13.8 (22.4) 
7.9 (6.7) 
7.3 (8.4) 
6.8 (3.6) 
Number of comorbid health 
conditions 
    0  
    1-2  
    3-4  
    5+ 
 
 
4.5 (1.7) 
3.5 (2.2) 
3.6 (1.7) 
1.3 (1.1) 
 
 
3.3 (3.4) 
2.7 (3.8) 
2.3 (2.9) 
6.0 (4.2) 
 
 
7.0 (6.3) 
6.3 (5.1) 
16.3 (22.1) 
4.3 (2.1) 
*Significant difference at p<0.05 
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ii. Substance use characteristics 
Substance use characteristics including primary substance of use (heroin, alcohol, crack 
cocaine, other), number of distinct drugs used (≤ 3, 4-9, 10+), and length of use (less than 
10 years, 10 to 29 years, 30+ years) were stratified according to total MMAS-8 score, 
self-reported adherence, and self-reported relapse rate. The results showed that there were 
no significant differences among these groups. The results of this analysis are shown in 
Table 9.  
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Table 9: Substance Use Characteristics Stratified by Adherence and Relapse 
Substance Use 
Characteristic  
Adherence  
(MMAS-8 score; 
mean, st dev) 
Adherence  
(self-report; 
mean, st dev) 
Relapses 
(self-report; 
mean, st dev) 
Primary substance of use: 
     Heroin 
     Alcohol 
     Crack cocaine 
     Other 
 
3.8 (2.1) 
3.3 (1.7) 
4.4 (1.8) 
1.7 (1.7) 
 
3.2 (3.7) 
2.3 (2.6) 
4.3 (4.4) 
3.3 (4.0) 
 
6.4 (5.9) 
16.6 (22.6) 
9.8 (7.6) 
3.0 (1.7) 
# of distinct drugs used 
     ≤ 3 
     4-9 
     10+ 
 
3.9 (2.4) 
3.4 (1.9) 
3.3 (1.5) 
 
4.2 (4.1) 
2.6 (2.9) 
2.5 (3.4) 
 
15.5 (24.1) 
7.8 (7.0) 
5.7 (2.3) 
Length of use 
     Less than 10 years 
     10 to 29 years 
     30+ years 
 
4.0 (2.0) 
3.4 (1.9) 
3.4 (2.2) 
 
2.4 (2.4) 
3.6 (3.6) 
2.7 (3.7) 
 
4.3 (3.1) 
7.2 (6.7) 
17.0 (22.4) 
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iii. Mental illness characteristics 
Mental illness characteristics including mental illness diagnosis (MDD, GAD, bipolar 
disorder, schizophrenia, more than one mental illness), self-reported mental illness 
severity level (1-6, 7-9, 10), number of psychotropic medications prescribed (1-2, 3-4, 
5+), presence of more than one mental illness (yes, no), PHQ-9 score (not present, mild, 
moderate, moderately severe, severe), MDQ score (negative, positive), and GAD-7 (not 
present, mild, moderate, severe) were stratified according to total MMAS-8 score, self-
reported adherence, and self-reported relapse rate. The BPRS scores were excluded from 
this analysis due to only two patients having schizophrenia and both patients received 
similar scores for severity level. The results showed that there were no significant 
differences among these groups. The results of this analysis are shown in Table 10.  
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Table 10: Mental Illness Characteristics Stratified by Adherence and Relapse 
Mental Illness Characteristic 
Adherence 
(MMAS-8 score; 
mean, st dev) 
Adherence 
(self-report; 
mean, st dev) 
Relapses 
(self-report; 
mean, st dev) 
Diagnosis 
     MDD 
     GAD 
     Bipolar Disorder 
     Schizophrenia 
     More than one mental illness 
 
3.6 (2.0) 
3.4 (2.3) 
4.0 (2.5) 
6.3 (2.5) 
3.1 (1.6) 
 
2.5 (3.3) 
2.3 (1.0) 
4.7 (4.1) 
5.5 (6.4) 
2.6 (3.3) 
 
5.9 (3.8) 
11.0 (10.9) 
9.0 (8.6) 
8.5 (2.1) 
11.2 (18.8) 
Self-reported severity 
     Low (1-6) 
     Medium (7-9) 
     High (10) 
 
2.2 (2.0) 
3.7 (1.7) 
3.8 (2.1) 
 
2.6 (2.5) 
3.1 (3.8) 
3.2 (3.4) 
 
4.0 (2.5) 
8.0 (5.3) 
13.3 (20.8) 
Number of psychotropic 
medications prescribed 
     1-2 
     3-4 
     5+ 
 
 
2.9 (1.4) 
3.9 (1.7) 
3.6 (2.9) 
 
 
2.6 (3.5) 
3.1 (3.4) 
3.4 (3.6) 
 
 
7.3 (5.5) 
10.4 (17.0) 
10.8 (14.9) 
Presence of more than one 
mental illness 
    Yes 
    No 
 
 
3.6 (1.8) 
3.5 (2.2) 
 
 
3.4 (3.7) 
2.4 (2.7) 
 
 
8.7 (7.3) 
10.2 (16.7) 
PHQ-9 
     Not present (0-4) 
     Mild (5-9) 
     Moderate (10-14) 
     Moderately severe (15-19) 
     Severe (20-27) 
 
3.5 ( ) 
- 
4.0 (1.3) 
3.2 (2.2) 
3.0 (1.8) 
 
0.0 ( ) 
- 
5.0 (4.0) 
0.8 (1.0) 
2.6 (3.6) 
 
9.0 ( ) 
- 
5.0 (2.2) 
5.2 (4.0) 
16.0 (23.9) 
MDQ 
    Negative screen 
    Positive screen 
 
3.8 (1.7) 
3.2 (2.1) 
 
3.3 (2.6) 
3.1 (3.6) 
 
18.3 (22.9) 
6.3 (5.1) 
GAD-7 
     Not present (0-4) 
     Mild (5-9) 
     Moderate (10-14) 
     Severe (15+) 
 
3.5 ( ) 
4.5 ( ) 
2.9 (1.7) 
3.4 (1.9) 
 
0.0 ( ) 
1.0 ( ) 
0.7 (1.2) 
3.6 (3.5) 
 
9.0 ( ) 
1.0 ( ) 
7.0 (1.7) 
14.0 (22.1) 
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iv. DAI-10 
Patients’ total score on the DAI-10 along with each individual item were stratified 
according to total MMAS-8 score, self-reported adherence, and self-reported relapse rate. 
While there were no significant differences in terms of total scores, there was 
significance at the individual item level. Patients who answered “True” to the statement 
“For me, the good things about medication outweigh the bad” had significantly higher 
self-reported adherence rate compared to those who answered “False” (3.3 vs 1.0, 
p=.001). Patients who answered “True” to the statement “I feel strange, or doped up, on 
medication” had significantly lower MMAS-8 scores (2.5 vs 4.0, p=.024) and 
significantly lower self-reported adherence scores (1.3 vs 3.9, p=.030). Patients who 
answered “True” to the statement “I take medications on my own free choice” had 
significantly higher self-reported adherence (3.3 vs 1.6, p=.033). Patients who answered 
“True” to the statement “It is unnatural for my mind and body to be controlled by 
medications” had significantly lower MMAS-8 scores (2.3 vs 4.2, p=.004). Lastly, 
patients who answered “True” to the statement “Taking medication will prevent me from 
having a breakdown” had significantly higher MMAS-8 scores (4.0 vs 2.5, p=.035). 
There were no significance differences in relapse rates for any questions in the DAI-10. 
The results of this analysis are shown in Table 11.  
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Table 11: DAI-10 Stratified by Adherence and Relapse 
Drug Attitude Inventory (DAI-10) 
Adherence  
(MMAS-8 
score; mean, 
st dev) 
Adherence  
(self-report; 
mean, st dev) 
Relapses 
(self-report; 
mean, st dev) 
Total score 
    Negative (<0) 
    Neutral (0) 
    Positive (<0) 
 
0.5 ( ) 
3.1 (1.9) 
3.7 (1.9) 
 
1.0 ( ) 
6.3 (4.7) 
2.8 (3.2) 
 
10 ( ) 
26.3 (42.1) 
8.2 (9.4) 
1. For me, the good things about medication outweigh the bad 
     True 
     False 
 
3.6 (2.0) 
3.1 (1.8) 
 
3.3 (3.5)* 
1.0 (0.0)* 
 
9.7 (14.7) 
9.3 (8.3) 
2. I feel strange, “doped up”, on medication 
     True 
     False 
 
2.5 (1.5)* 
4.0 (2.0)* 
 
1.3 (1.1)* 
3.9 (3.8)* 
 
11.6 (20.2) 
8.8 (10.6) 
3. I take medications of my own free choice 
     True 
     False 
 
3.5 (2.0) 
3.7 (1.4) 
 
3.3 (3.6)* 
1.6 (0.9)* 
 
10.6 (14.9) 
3.4 (2.6) 
4. Medications make me feel more relaxed 
     True 
     False 
 
3.7 (1.9) 
2.8 (2.3) 
 
3.2 (3.4) 
2.3 (3.8) 
 
7.9 (9.5) 
17.4 (26.2) 
5. Medication makes me feel tired and sluggish 
     True 
     False 
 
3.2 (1.9) 
3.9 (2.0) 
 
3.5 (3.7) 
2.6 (3.0) 
 
7.5 (6.50 
11.9 (18.9) 
6. I take medication only when I feel ill 
     True 
     False 
 
2.8 (1.4) 
3.7 (2.1) 
 
3.1 (2.9) 
3.0 (3.6) 
 
5.6 (3.4) 
10.8 (15.7) 
7. I feel more normal on medication 
     True 
     False 
 
3.8 (1.9) 
2.2 (1.6) 
 
2.9 (3.3) 
3.7 (4.2) 
 
8.2 (9.7) 
17.8 (28.2) 
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8. It is unnatural for my mind and body to be controlled by medications 
     True 
     False 
 
2.3 (1.5)* 
4.2 (1.9)* 
 
2.6 (3.0) 
3.3 (3.6) 
 
15.4 (22.6) 
6.7 (5.0) 
9. My thoughts are clearer on medication 
     True 
     False 
 
3.7 (2.0) 
3.0 (1.9) 
 
3.0 (3.5) 
3.3 (3.3) 
 
8.3 (9.6) 
13.1 (21.9) 
10. Taking medication will prevent me from having a breakdown 
     True 
     False 
 
4.0 (2.0)* 
2.5 (1.5)* 
 
3.1 (3.5) 
3.0 (3.2) 
 
10.7 (16.1) 
7.1 (7.2) 
*Significant difference at p<.05; Use of the ™©MMAS is protected by US and International trademark and copyright laws. Permission for use is required. 
A license agreement is available from: Donald E. Morisky, MMAS Research) LLC; 14725 NE 20th St.; Bellevue, WA 98007. Pertinent citations include: (1) 
Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension control. Journal of Clinical 
Hypertension 2008; 10(5):348-354. (2) Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE, Muntner P. New medication adherence scale versus 
pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-
reported medication nonadherence: Final response. J Clin Epidemi 2011; 64:258-263. 
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c. Adherence measurements and relapse correlation coefficients  
Correlation coefficients were computed among the four different measurements of 
adherence and patients’ self-reported relapse rate. The four adherence measurements 
included were the MMAS-8 total score, MMAS-8 intentional score, MMAS-8 
unintentional score, and self-report adherence rate. The results of the correlation analyses, 
presented in Table 12, showed that self-reported relapse rate was negatively correlated 
with the MMAS-8 intentional score (r= -.360, p=.026). MMAS-8 total score was 
positively correlated with self-reported adherence rates (r=.618, p<.001), the MMAS-8 
intentional score (r=.869, p<.001), and the MMAS-8 unintentional score (r=.863, 
p<.001).  MMAS-8 intentional score was positively correlated with MMAS-8 
unintentional score (r=.552, p<.001) and self-reported adherence rate (r=.613, p<.001). 
Lastly, the MMAS-8 score was positively correlated with self-reported adherence rate 
(r=.481, p<.001).  
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Table 12: Correlation Between Adherence and Relapse 
Pearson Correlation 
Coefficient (r) 
Self-report 
Relapse Rate 
MMAS-8 
Total Score 
MMAS-8 
Intentional Score 
MMAS-8 
Unintentional Score 
MMAS-8  
Total Score 
-.296    
MMAS-8  
Intentional Score 
-.360* .869**   
MMAS-8 
Unintentional Score 
-.139 .863** .552**  
Self-reported 
Adherence Rate 
-1.23 .618** .613** .481** 
**Significant at p<.001; *Significant at p<.05; Use of the ™©MMAS is protected by US and International 
trademark and copyright laws. Permission for use is required. A license agreement is available from: Donald E. 
Morisky, MMAS Research) LLC; 14725 NE 20th St.; Bellevue, WA 98007. Pertinent citations include: (1) Morisky 
DE, Ang A, Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension 
control. Journal of Clinical Hypertension 2008; 10(5):348-354. (2) Krousel-Wood MA, Islam T, Webber LS, Re RS, 
Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am 
J Manag Care 2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-reported 
medication nonadherence: Final response. J Clin Epidemi 2011; 64:258-263. 
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d. Linear regression model 
A multiple regression analysis was conducted to evaluate how well certain study 
measures predicted self-reported relapse rate. The predictors were MMAS-8 total score, 
self-reported mental illness symptom severity level, mental illness type, length of 
substance use and DAI total score. All variables except for mental illness type were 
classified as continuous variables. Mental illness type was classified as a nominal 
variable composed of the following groups: MDD, GAD, bipolar disorder, schizophrenia, 
2+ mental illnesses. The assumptions for linear regression models were assessed before 
running the model. The Shapiro-Wilk Test was utilized to assess normality and the VIF 
collinearity statistic was utilized to assess collinearity. The linear combination of the 
study measures included in the model was not significantly related to self-reported 
relapse rate (F=2.25, adjusted R2 =.145, p=.073). Table 13 shows the relative strength of 
each individual predictor. The regression model shows that MMAS-8 total score is a 
significant predictor of relapse rate when adjusting for the other included study measures 
(stand. beta = -.443, CI= -6.37-0.23, p=.048).  
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Table 13: Linear Regression Model 
 
Self-report Relapse Rate (n=38) 
Stand. beta 95% CI p-value 
Constant   -25.84 to 17.14   
MMAS-8 total score -.443 -6.37 to -0.23 0.048* 
Mental illness symptom 
severity (self-reported) 
.314 -0.41 to 5.00 0.093 
Mental illness type -.141 -2.90 to 1.26 0.429 
Length of substance use .287 -0.30 to 0.62 0.074 
DAI total score .173 -0.98 to 2.37 0.402 
*Significant difference at p<.05; Use of the ™©MMAS is protected by US and International trademark and 
copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, MMAS 
Research) LLC; 14725 NE 20th St.; Bellevue, WA 98007. Pertinent citations include: (1) Morisky DE, Ang A, 
Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension control. Journal of 
Clinical Hypertension 2008; 10(5):348-354. (2) Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE, 
Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 
2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication 
nonadherence: Final response. J Clin Epidemi 2011; 64:258-263. 
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IV. Objective 4 
Assess follow-up changes in mental illness severity and medication adherence in dual 
diagnosis patients enrolled in a substance abuse rehabilitation program 
a. Follow-up rates 
As stated in previously, follow-up interviews were conducted with patients at one-month 
and two months post-primary interview. A total of 12 patients (31.6%) fully completed 
the study with two follow-ups, 15 patients (39.5%) participated in the first follow-up then 
dropped out of the study, and 11 patients (28.9%) only participated in the primary 
interview before dropping out. Reasons for patient drop-out included being caught using 
drugs on the Harbor Light Center premises, not complying with center rules, not 
believing that their addiction was severe enough to warrant treatment, overdosing on the 
premise and being admitting to the hospital, being found in possession of illicit 
substance, leaving the program to be with a significant other, leaving the program with 
intention to continue substance use, completing the program early, testing positive for 
illicit substances, using illicit substance while on leave, and simply leaving the program 
without giving a reason. 
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b. Patient and clinical characteristics by follow-up 
Patient characteristics were stratified according to follow-up interviews completed. The 
characteristics included in this analysis were age, MMAS-8 total score, MMAS-8 
intentional score, MMAS-8 unintentional score, self-reported adherence rate, mental 
illness type, mental illness symptom severity, substance of choice, DAI-10 total score, 
receiving income, and housing situation. The results of this analysis are shown in Table 
14. The DAI-10 total score was significantly lower in patients who only completed the 
primary interview vs. patients who completed the study entirely (4.0 vs 7.0, p=.044). All 
other comparisons were statistically insignificant.  
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Table 14: Patient and Clinical Characteristics by Follow-up 
Characteristics 
Mean, st dev unless specified 
Primary 
(n=11) 
1st Follow-up 
(n=15) 
2nd Follow-up 
(n=12) 
p-value 
Age 41.2 (11.5) 40.5 (11.1) 40.8 (12.7) 0.990 
MMAS-8 total score 3.2 (1.5) 3.2 (1.8) 4.3 (2.0) 0.300 
Adherence (self-report) 3.8 (3.5) 2.6 (3.3) 2.9 (3.6) 0.667 
Mental illness type, n (%) 
     MDD 
     GAD 
     Bipolar 
     Schizophrenia 
     2+ 
 
1 (2.6) 
1 (2.6) 
2 (5.3) 
1 (2.6) 
6 (15.8) 
 
2 (5.3) 
1 (2.6) 
3 (7.9) 
0 (0.0) 
9 (23.7) 
 
4 (10.5) 
2 (5.3) 
1 (2.6) 
1 (2.6) 
4 (10.5) 
0.670 
Symptom severity 8.2 (1.5) 8.3 (2.5) 8.8 (1.4) 0.748 
Drug of choice, n (%) 
     Heroin 
     Alcohol 
     Crack cocaine 
     Alcohol and crack  
     Marijuana 
     Methamphetamine 
 
4 (10.5) 
4 (10.5) 
2 (5.3) 
0 (0.0) 
1 (2.6) 
0 (0.0) 
 
9 (23.7) 
4 (10.5) 
1 (2.6) 
0 (0.0) 
0 (0.0) 
2 (5.3) 
 
6 (15.8) 
4 (10.5) 
1 (2.6) 
1 (2.6) 
0 (0.0) 
0 (0.0) 
0.634 
DAI total score 4.0 (2.8)* 5.1 (2.3) 7.0 (3.4)* 0.044* 
Relapse rate (self-report) 8.5 (8.0) 10.6 (18.5) 9.7 (13.0) 0.933 
Receiving income, n (%) 
     Yes 
     No 
 
0 (0.0) 
11 (28.9) 
 
3 (7.9) 
12 (31.6) 
 
4 (10.5) 
8 (21.1) 
0.117 
Housing situation, n (%) 
     Homeless 
     Living with family 
     Other 
 
9 (25.0) 
0 (0.0) 
1 (2.8) 
 
13 (36.1) 
0 (0.0) 
1 (2.8) 
 
8 (22.2) 
2 (5.6) 
2 (5.6) 
0.272 
*Significant difference at p<.05; Use of the ™©MMAS is protected by US and International trademark and 
copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, MMAS 
Research) LLC; 14725 NE 20th St.; Bellevue, WA 98007. Pertinent citations include: (1) Morisky DE, Ang A, 
Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension control. Journal of 
Clinical Hypertension 2008; 10(5):348-354. (2) Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE, 
Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 
2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication 
nonadherence: Final response. J Clin Epidemi 2011; 64:258-263. 
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c. Changes in adherence 
At each interview, patients reported their adherence on a scale from 1 to 10. These self-
reported adherence rates were analyzed in order to assess for significant change in 
adherence over time while enrolled in the rehabilitation program. The results showed a 
significant change in adherence during the first follow-up interview compared to the 
primary interview (mean difference=5.7, p<.001) and a significant change in adherence 
during the second follow-up interview compared to the primary interview (mean 
difference=6.5, p<.001). There was no significant change in adherence between the first 
follow-up interview and the second follow-up interview. The results of this analysis are 
shown in Table 15.  
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Table 15: Changes in Adherence 
Adherence (self-report) Mean difference (st dev) p-value 
Primary interview vs. 
1st follow-up 
5.7 (3.7) <.001* 
Primary interview vs. 
2nd follow-up 
6.5 (3.7) <.001* 
1st follow-up vs. 
2nd follow-up 
0.17 (0.9) 0.551 
*Significant difference at p<.05 
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CHAPTER 5 – CONCLUSION  
I. Discussion 
The overall goal of the study’s first objective was to gain better insight into the dual 
diagnosis patient population. The demographic data collected through the study 
demonstrated that the study population is an extremely vulnerable population who need 
both mental health and substance use treatment. The study population is characterized as 
predominately indigent, of lower educational status, homeless, white, middle-aged men. 
The majority of these men were engaging in the use of drugs such as heroin or crack 
cocaine, and have been using drugs since they were young teenagers. The results of this 
long-term use are highlighted by the high amount of comorbid health conditions in the 
patients. The high rate of previous substance use treatments and relapse rates may lead 
one to extrapolate that these patients are somewhat aware that they are engaging in an 
unhealthy and dangerous lifestyle but they lack the ability to stop even if they are actively 
trying to. While the previous statement is a plausible conclusion, it is important to be 
cognizant of the fact that SUD is a defined mental illness driven by addiction and 
characterized by irrational behavior.  
 
The population also suffers from severe mental illnesses, and in most cases more than 
one diagnosis. During the primary interviews, patients were given both mental illness 
severity measurement tools and asked to self-report their symptom severity on a scale 
from 1 to 10. The results from the mental illness severity measurements and patient self-
report show that not only are the patients suffering from severe mental illnesses but they 
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are also aware of the severity of their symptoms. Yet, patients in this population are not 
taking the medications prescribed to them to aid in the treatment of their diagnoses. Both 
the patient’s self-report and the MMAS-8 show that adherence to psychotropic 
medications is severely low within this population. The overwhelmingly positive results 
of the DAI-10 show that patients are fully aware of the benefits of psychotropic 
medications yet still lack the ability to take them as prescribed. When asked why they 
were not taking their medications properly, a majority of patients cited reasons related to 
their drug habits such as ‘being too inebriated to remember’ and fearing dangerous drug 
interactions. Many patients even displayed an awareness that they are self-medicating 
their mental illness with illicit drugs. The concepts of cognitive impairment and self-
medicating may offer an explanation of why there is a gap between patients knowing 
their condition yet not taking their medications. Cognitive impairment is a common 
symptom of both SUD and mental illness that harms certain areas the patient’s mental 
functioning including critical thinking, memory, attention, and motivation.213 Therefore, 
patients in the study may lack the cognitive ability to maintain a prescription regimen 
even when they are actively trying. In regard to self-medicating, previous literature has 
proven that this is a common problem within the dual diagnosis population. In a large 
nationally representative survey of 43,093 adults with mental illness, Bolton et al. found 
that 25% of individuals with mental illness used drugs or alcohol to relieve their 
symptoms.214 Therefore, it can be concluded that patient within our study may be actively 
choosing to relieve their mental illness symptoms using illicit drugs even if they are 
aware of the benefits of psychotropic medications. In other words, the patients may 
simply prefer drugs of abuse over psychotropic medications.  
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Outside of mental impairment and self-medicating, another way to explain the conflicting 
beliefs of patients being aware of their mental illness and wanting to recover from their 
substance abuse problem yet not taking their medications is to conclude that patients are 
not aware of how properly treating their mental illness will benefit their goal of quitting 
substance abuse. Patients may believe that their mental illness and SUD are two unrelated 
diseases that are to be treated separately. Therefore, they may be currently attempting to 
treat their SUD through rehabilitation while not properly treating their co-occurring 
mental illness.  
 
The results from the study’s first objective are on par with previous literature. First our 
study concluded found that the study population suffered from a high level of mental 
illness symptom severity. Previous studies have also concluded that patients with SUD 
are likely to suffer from more severe mental illness symptoms compared to those who do 
not have a SUD. For example, a study conducted by Ries et al. measured the mental 
illness severity in 104 patients admitted to an acute voluntary psychiatric unit. The study 
concluded that patients with a current SUD had significantly more severe symptoms 
compared to those who did not.215 Secondly, our study found that the patients included in 
the study displayed an extremely low level of adherence. As discussed in the literature 
review, psychotropic medication nonadherence is common in patients with SUD. Our 
literature review found that 36 of the 51 studies (71%) concluded that comorbid 
substance use was significantly associated with psychotropic medication nonadherence. 
134,137,146-149,151-153,155,156,158-165,167,168,170,174-176,178,180-183,185-189,194 134,137,146-149,151-153,155,156,158-
165,167,168,170,174-176,178,180-183,185-189,194 Of these 36 studies, 18 (35%) identified substance use 
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as a predictor of nonadherence. Yet, these studies vary in adherence measurement 
methods when compared to our study. In a previous study conducted by Dunn et al., the 
MMAS-8 scale was used to measure medication adherence in 316 patients with co-
occurring psychiatric disorders and SUD enrolled in an addiction treatment program. It 
appears that this is the only other study that has utilized the MMAS-8 scale in the dual 
diagnosis population. The researchers concluded that 80.4% of the patients enrolled in the 
study scored as adherent on the MMAS-8.216 These results are contrary to both the results 
found in our study and the results found in the majority of the studies within the literature 
review. Lastly, our study’s first objective found that patients displayed an overall positive 
attitude towards their psychotropic medications according the DAI-10 results. In a 
previous study conducted by Cuevas et al., 270 psychiatric outpatients were given the 
DAI-10 along with 292 citizens with no history of mental illness or psychotropic 
medications. The psychiatric patients showed an overall more positive attitude compared 
to the general population, with a mean DAI-10 score of 3.6 compared to -0.7.217 These 
DAI-10 scores are similar to the overall DAI-10 mean of 5.4 that was measured in our 
study population.  
 
The goal of the study’s second objective was to measure agreeance between patient-self 
reported data using facility records in order to determine if the dual diagnosis population 
is a reliable source of data for research. While the majority of the data collected from the 
facility records was patient self-reported, the patients’ mental illness diagnosis and 
medications prescribed were supplemented by medical records. It is important to test this 
relationship not only to confirm the agreeance of the data but also to test patients’ disease 
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insight, which is the ability to understand the nature of their illness. Patients with low 
disease insight are more difficult to treat and experience worse health outcomes.218 
Before conducting the study, it was hypothesized that the data gathered from patients 
would be somewhat inaccurate due to the mental state of the patients who are providing 
the data. Multiple previous studies have measured disease insight in patients with heroin-
use disorder,219 bipolar disorder,220 schizophrenia,221 depression222 and mental illness in 
general.223 These studies have unanimously concluded that patients in their respective 
population exhibit significantly low disease insight or awareness. Contrary to our 
hypothesis and previous research, the patients in our study displayed a high awareness 
and knowledge of their current health status by accurately reporting information about 
their mental illness diagnoses and psychotropic medications. The high correlation 
between patients’ report of adherence and all three MMAS-8 scores also highlights the 
accuracy of the adherence information provided by patients. This finding may be due to 
the Harbor Light intake protocol and the other processes the patients go through before 
admission. The majority of patients come to Harbor Light from detoxification or other 
health care settings such as hospitals emergency departments. In these settings and 
through Harbor Light intake procedures, patients may have been reminded of their 
disease states. Since the primary interview took place within a week of admission, the 
patients were more likely to remember their mental illness compared to others in the dual 
diagnosis population. It is important to note that agreeance was higher for primary 
substance of use compared to the other variables. The researchers hypothesize that this 
outcome occurred due to substance use history being the only patient controlled variable 
included in the analysis.   
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The goal of the study’s third objective, which was the primary objective of the study, was 
to investigate the specific role of medication adherence and barriers to use for 
psychotropic medications upon SUD relapse. The results of the DAI-10 stratification 
showed that low adherence is a result of patients having negative attitudes towards their 
psychotropic mediations or not believing that these medications play a vital role in their 
mental illness treatment yet it was found that these attitudes and beliefs do not play a role 
in patients relapsing back to substance use. The researchers hypothesize that the 
insignificant relapse outcome was caused by large standard deviations due to only one 
patient expressing negative attitudes and 34 expressing positive attitudes. The conclusion 
that negative attitudes towards psychotropic medication leads to low adherence is 
supported by previous literature. In a study conducted by Brown et al, attitudes and 
beliefs about antidepressant medications were measured in patients in a primary care 
setting. Patients’ attitudes were measured using the Beliefs about Medicines 
Questionnaire (BMQ), the measurement that the DAI-10 is based on. The researchers 
concluded that positive beliefs about medications were significantly associated with self-
reported adherence.224 Another study conducted by Brain et al. observed the effect of 
drug attitude on medication adherence in 112 outpatients with schizophrenia and 
schizophrenia-like psychosis. The DAI-10 was utilized to measure drug attitudes and a 
medication event monitoring system was utilized to measure adherence. A univariate 
regression model showed that a negative DAI-10 score was a predictor of non-
adherence.225 
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The study’s third objective also found that there was a significant correlation between 
patients’ nonadherence to psychotropic medications and SUD relapse. This relationship 
was then analyzed further using a regression model, which concluded that the linear 
combination of the included variables was not significant. The researchers hypothesized 
that this outcome was due to the influence of the underpowered study sample size on the 
model’s F statistic, even though all 38 patients were included in the model and no 
missing data was prevalent. Yet, the model concluded that adherence is a significant 
predictor of substance abuse relapse when other study variables were incorporated into an 
adjusted analysis. Therefore, the results of the study can lead one to conclude that dual 
diagnosis patients’ nonadherence to psychotropic medications is related to substance 
abuse relapse. Our study is currently the first study in the literature to observe this 
specific relationship within the dual diagnosis population and to make this conclusion.  
 
While there may be multiple explanations as to why a relationship was found, the act of 
self-medicating may explain the gap between psychotropic medication nonadherence and 
SUD relapse. Patient were not adherent their psychotropic medications due to multiple 
factors including negative attitudes towards their medications. As discussed in the 
background section, nonadherence leads to increased mental illness symptom severity. As 
their symptoms increase, patients may be choosing to treat their mental illness with illicit 
drugs instead of prescribed medication therefore leading them back to SUD relapse. A 
study focused on patients self-medicating would need to be conducted in the future in 
order to confirm this hypothesis.  
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The goal of the study’s fourth and final objective was to assess differences between 
patients who stayed in the study versus those who did not and to observe changes in 
behavior while in rehabilitation. This was done by following patients over three months 
through follow-up interviews. Less than one third of the total participants continued the 
study to its completion. This high drop-out rate was initially expected due to the nature of 
the study population. All patients who dropped out of the study also dropped out of the 
rehabilitation program, therefore no patient specifically chose to discontinue study 
participation while still pursing treatment. Patient drop-outs were simply a secondary 
result of patients not continuing drug addiction treatment and was not due to the study 
itself. The drop-out rate within our study is similar to substance abuse treatment program 
dropout rates found within previous literature. The typical treatment drop-out rate within 
the first month of treatment is 30% and the rate rises to 50% at 3 months.226 Our study 
had a drop-out rate of 28.9% within the first month and a drop-out rate of 68.4% at three 
months. The study found that patients who completed the entire study displayed more 
positive attitudes and beliefs towards the psychotropic medications they are prescribed. 
Since all patients who dropped out of the study also discontinued their substance abuse 
treatment, this relationship offers valuable insight into the importance of patients fully 
understanding why they should be taking their medications and the vital role it plays in 
rehabilitation. Lastly, the study found that patients’ adherence increased over time while 
in the rehabilitation center. Harbor Light Center’s staff does not force patients to take 
their mediations nor do they monitor medication taking behavior at a clinical level. 
Therefore, one can conclude that the drug abuse rehabilitation intervention played a 
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significant and vital role in increasing psychotropic adherence which, as the study has 
shown, decreases their likelihood of substance abuse relapse.  
 
II. Study Implications 
The results of the study provide valuable insight into the relationship between 
psychotropic medication adherence and substance abuse relapse in patients with dual 
diagnosis. It is evident from the study findings that dual diagnosis patients’ adherence 
and attitudes towards their psychotropic medication play a significant role in substance 
use relapse. The results of the study can be applied to real-world treatment of dual 
diagnosis in the following ways.  
 
First, the study results provide a better understanding into the dual diagnosis population 
and can be used by drug abuse rehabilitation programs in order to target patients more 
effectively and increase treatment outcomes. Interventions can now identify patients that 
are at a higher risk of substance use relapse therefore giving them the ability to provide 
more centralized and individually tailored treatment to those who need it the most. Since 
the main outcome of most rehabilitation interventions is preventing substance use relapse, 
an increased understanding of what causes that outcome is extremely valuable. 
Interventions should incorporate education about the importance of psychotropic 
medication adherence and mental illness treatment into their programs therefore helping 
patients attain their cessation goals. While Harbor Light does encourage their patients to 
take their psychotropic medications, adherence should become an integral part of their 
treatment program. Periodic assessments of adherence should take place while patients 
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are in treatment in order to guarantee that patients are staying adherent. Harbor Light 
should also provide adherence counseling and adherence motivational interviewing to 
their patients. As discussed in the literature review, standard SUD treatment combined 
with motivational interviewing has been shown to significantly increase adherence 
among dual diagnosis patients.190 The most noteworthy challenges of working within this 
population was the patients’ lack of accuracy and reliability when reporting health-related 
variable. Therefore, these counseling sessions should also focus on improving health 
literacy in order to increase disease awareness and improve outcomes. Since our study 
found that negative attitudes towards medications are related to nonadherence, these 
counseling sessions should also educate patients on the short-term and long-term effects 
of medication, how the medication works, and the role adherence plays in SUD 
treatment.  
 
Second, the results from the study can be utilized by healthcare professionals. The study 
highlights the importance of physicians integrating the treatment of mental illness and 
SUD in dual diagnosis patients due to the negative effect each disease has on the other. 
SAMHSA has recently published a report, titled Integrated Treatment for Co-Occurring 
Disorders: The Evidence, which highlights the importance of integrated dual diagnosis 
treatment along with previous evidence that concluded combined treatment results in 
more positive outcomes.227 The third objective of our study found that nonadherence is 
related to SUD relapse. Therefore, physicians should provide adherence counseling to 
patients with a history of SUD before they are prescribed psychotropic medications and 
continuously through their treatment. These counseling sessions should consist of 
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adherence strategies, expected side effects, potentially dangerous drug-drug interactions, 
and the benefits on staying adherent. Phone counseling can be utilized to ease the burden 
on patients who are unable to or not willing to return to the physician’s office. Since self-
reported adherence may not be accurate in this population, physicians could use 
electronic pill bottles to measure adherence behaviors more accurately between 
appointments. Since these patients are uniquely difficult to treat using typical mechanism 
such as primary care, social and case workers may also be more effective in 
implementing these changes.  
 
The results of our fourth objective highlight the importance of following-up with patients 
after they leave treatment in order to guarantee the continuation of adherence. While 
follow-ups may be more difficult to conduct in this population, many techniques can be 
utilized. Short message service (SMS) based interventions have been shown to both 
improve adherence in patients with mental illness 228 and improve drug abstinence in dual 
diagnosis patients.229 Significant others or family members without SUDs could also be 
included to help prevent patients discontinuing the interventions. The use of mobile 
interventions will result in a faster detection of nonadherence therefore giving 
interventions the ability to provide help before the patient reverts back to illicit drug use.  
 
III. Limitations 
The study contains some potential limitations that may have impacted the results, and 
need to be addressed in order for the study outcomes to be properly interpreted. First, due 
to some study characteristics, the results may not be generalizable. The study finished 
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data collection with low sample size due to it being intentionally designed as a feasibility 
study. Also, the study only contained males in the sample since Harbor Light Center is a 
male only facility. Therefore, the results may not be generalizable to females with dual 
diagnosis. The study only included patients with major depressive disorder, generalized 
anxiety disorder, bipolar disorder, and schizophrenia. Although these are among the most 
prevalent mental illnesses, the results may not be generalizable to patients with other 
mental illnesses such as attention-deficit disorder or post-traumatic stress disorder.  
 
Second, the information reported by patients may be subject to recall bias. Almost all of 
the information collected from the patients is retrospective and the patients may have 
been cognitively impaired during that time period. For example, one patient was required 
to recall the number of relapses he experienced during a 40-year history of substance use. 
The inclusion of facility records attempted to minimize this effect since the patients’ 
mental health information was supplemented by health records.  
 
Third, the results may be subject to social desirability bias. Since all patients were 
interviewed within their first week of treatment, patients may have embellished their 
adherence levels or restrained from revealing all of their past substance use in order to 
exhibit their ability to succeed in the program. Also, question #9 of the PHQ-9 asked the 
patients if they have ever had “Thoughts that you would be better off dead or of hurting 
yourself in some way.” One patient expressed a concern that there would be 
consequences if he answered that question honestly. The impact of social desirability bias 
should be minimal due to the study design. The researcher began each interview by 
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reiterating to the patient that no information would be shared with the Harbor Light 
Center staff and that the interview would have no effect on their treatment in the 
program. If the patients were aware that the information they gave during interviews was 
completely confidential, there would be no reason to embellish or lie about their 
adherence levels or substance use characteristics.  
 
Fourth, the patients’ low health literacy may have affected the accuracy of the self-
reported data.  Multiple patients showed signs of not fully understanding the concept of 
adherence, even after it is explained to them. For example, patients often self-reported a 
‘10’ on adherence but then admitted to occasionally missing doses. One patient self-
reported a ‘10’ on adherence but admitted to breaking all of his pills in half for every 
dose so the medication lasted longer. He also saw nothing wrong with doing this since it 
was saving money. In reality, this would be classified as extremely low adherence or 
even considered zero adherence. The researcher thoroughly explained the concept of 
adherence to each patient and expressed willingness to explain any material to patients 
during all interviews. The interviewer also attempted to assess if the patient understood 
all of the questions included in the self-reported assessments. Therefore, the impact of 
this limitation should not be significant. Similar future research should consider 
measuring patient health literacy and adjusting for it within the statistical analysis.  
 
IV. Opportunities for Future Research 
Based on the results of the study, one can conclude that psychotropic nonadherence plays 
a significant role in regard to substance abuse relapse in the dual diagnosis population. 
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While this is a significant and impactful finding, further research is needed in order to 
gain a more in-depth understanding in regard to the connection between adherence and 
SUD relapse. The researchers suggest that future studies take the following approaches. 
First, a larger study with a greater sample size and wider geographic coverage observing 
the same relationship would produce a better understanding of the relationship. Second, 
while the study established nonadherence as a predictor of relapse, a more in-depth study 
analyzing the causation of nonadherence within the dual diagnosis population would 
better help interventions improve adherence therefore preventing relapse. The researchers 
suggest a more in-depth qualitative study surrounding patients self-medicating in order to 
discover why patients are choosing illicit drugs over psychotropic medications for 
treating their psychiatric symptoms. These studies should also establish a more accurate 
approach to measuring symptom severity across the sample. While our study used 
established tools such as the PHQ-9 and the MDQ, these results could not be compared 
across disease states. Third, while the study established that adherence improved while in 
treatment, no information was gathered on patients after they completed the program or 
dropped out. Patients’ adherence levels were established during the primary interview 
and measured through the 90-day treatment period. While the study concluded that 
adherence improved during this period, this conclusion cannot be assumed to hold true 
after the patient leaves the program since they are going from a controlled environment to 
an uncontrolled environment. A future study should follow patients for a longer amount 
of time, even after rehabilitation completion, collecting substance abuse and relapse 
information in order to assess if the changes in adherence made during treatment are 
permanent. This may prove to be difficult since a majority of the patients were homeless 
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before admission. We suggest researchers conduct phone interviews or invite patients to 
return back to the facility after completing the program and establish a way to pay the 
patients for their time. A future study should also conduct exit interviews with patients 
who completed the program in order to assess variables that influenced successful 
treatment. Lastly, a future study should assess the impact of a rehabilitation centers 
educating patients on the importance of adherence in order to determine if interventions 
that focus on increasing patient knowledge in regard to adherence would indeed lead to a 
decrease in relapse.  
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APPENDICES 
 
APPENDIX 1: Facility Record Data Collection Form 
 
1. Patient ID: 
 
2. Year of birth: 
 
3. Race/ethnicity (Caucasian, Black/African American, Hispanic, other): 
 
4. Employment status prior to relapse: 
 
5. Approximate income level prior to admission: 
 
6. Educational background (less than high school, high school, more than high 
school): 
 
7. Housing situation prior to admission: 
 
8. Description of family support: 
 
9. Primary substance of abuse/choice: 
 
a. Other substances utilized: 
 
10. Age at substance use initiation: 
 
11. Length of use reported: 
 
12. Number of previous admissions to Harbor Light facility: 
 
13. Number of other admissions to rehabilitation programs: 
 
14. Mental illness diagnoses: 
a. Patient-reported: 
b. Medically-assigned: 
 
15. Age at mental illness diagnosis: 
 
16. Severity of mental illness prior to admission: 
 
17. Mental illness treatments (pharmacological or non-pharmacological): 
a. Previously utilized: 
b. Currently prescribed: 
 
18. Level of medication adherence: 
 
19. Medical comorbidity diagnoses:  
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APPENDIX 2: Prospective patient interview form 
 
1. What is your primary drug of abuse? What other drugs have you utilized in addition to 
your primary drug of abuse? 
 
2. How long have you been using your primary drug of abuse? 
 
3. How many times have you relapsed in your substance use prior to this facility? 
 
4. How many times have you been in treatment for substance use prior to this facility? 
 
5. What factors do you believe have contributed to your relapse this time? 
 
6. Have you ever been diagnosed with a mental illness by a healthcare professional? If so, 
what diagnoses? 
 
7. Think back to your mental illness symptoms prior to entering treatment (excluding 
withdrawal symptoms). On a scale of 1 to 10 (1 = no symptoms and 10 = very severe 
symptoms), how would you rate the severity of your mental illness symptoms (insert 
appropriate example below)? 
 
a. Depression – e.g. low energy, lack of appetite, lack of motivation 
b. Bipolar disorder – e.g. mood swings, periods of excessive energy or depression 
c. Generalized anxiety – e.g. persistent worrying, inability to relax, distress 
d. Schizophrenia – e.g. hallucinations, delusions 
 
8. Have you received any medication for your mental illness from a healthcare professional?  
 
a. If so, what medications are you currently taking? 
b. If so, what medications have you previously taken? 
 
9. Often times, people do not take their medication as prescribed. On a scale of 1 to 10 (1 = 
taken no doses and 10 = taken all doses as prescribed), how would you rate adherence to 
your medication for your mental illness? 
 
10. What factors do you believe have contributed to you not taking your medication? 
 
11. Have you ever been diagnosed with other long-term medical conditions by a healthcare 
professional, such as hepatitis C, diabetes, high blood pressure? If so, what diagnoses? 
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APPENDIX 3: Longitudinal follow-up questions 
 
1. Since leaving the Harbor Light facility, have you resumed use of any alcohol or other 
drugs of abuse (for example, prescription opioids, cocaine, marijuana, or heroin)? 
 
2. If relapsed, how long after leaving the Harbor Light facility did this occur? 
 
3. If relapsed, have you sought treatment for your substance use? 
 
4. Since leaving the Harbor Light facility, how have your symptoms of your mental illness 
changed (insert appropriate example(s) of symptoms below) – (1) no current symptoms, 
(2) symptoms deceased, (3) symptoms increased, (4) symptoms remained the same? 
Please explain. 
 
a. Depression – e.g. low energy, lack of appetite, lack of motivation 
b. Bipolar disorder – e.g. mood swings, periods of excessive energy or depression 
c. Generalized anxiety – e.g. persistent worrying, inability to relax, distress 
d. Schizophrenia – e.g. hallucinations, delusions 
 
5. Often times, people do not take their medication as prescribed. Since leaving the Harbor 
Light facility, on a scale of 1 to 10 (1 = taken no doses and 10 = taken all doses as 
prescribed), how would you rate adherence to your medication for your mental illness? 
 
6. If you have not taken your medication as prescribed, what factors do you think have 
contributed to you not taking your medication? 
 
[Offer for contact with care coordinator at Harbor Light if patient expresses increased 
symptoms or reports relapse to substance use] 
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APPENDIX 4: The Morisky Medication Adherence Scale (MMAS-8) 
 
Use of the ™©MMAS is protected by US and International trademark and copyright 
laws. Permission for use is required. A license agreement is available from: Donald E. 
Morisky, MMAS Research) LLC; 14725 NE 20th St. Bellevue WA 98007. 
 
Pertinent citations include: 
 
▪ Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive validity of a 
medication adherence measure for hypertension control. Journal of Clinical 
Hypertension 2008; 10(5):348-354. 
▪ Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE, Muntner P. New 
medication adherence scale versus pharmacy fill rates in seniors with 
hypertension. Am J Manag Care 2009;15(1):59-66. 
▪ Morisky DE, DiMatteo MR. Improving the measurement of self-reported 
medication nonadherence: Final response. J Clin Epidemi 2011; 64:258-263. 
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APPENDIX 5: The Drug Attitude Inventory (DAI-10) 
 
 
 
 
 
Hogan TP., Award AG., Eastwood R. A self report scale predictive of drug compliance in 
schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183. 
 
Reproduced with permission  
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APPENDIX 6: The Patient Health Questionnaire (PHQ-9) 
 
 
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression 
Severity Measure. Journal of General Internal Medicine. 2001;16(9):606-613. 
doi:10.1046/j.1525-1497.2001.016009606.x. 
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APPENDIX 7: The Mood Disorder Questionnaire (MDQ) 
 
                                                                                                                                                                                
Hirschfeld RMA. The Mood Disorder Questionnaire: A Simple, Patient-Rated Screening 
Instrument for Bipolar Disorder. Primary Care Companion to The Journal of Clinical 
Psychiatry. 2002;4(1):9-11. 
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APPENDIX 8: The Generalized Anxiety Disorder Assessment (GAD-7) 
 
 
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. A brief measure for assessing 
generalized anxiety disorder: the GAD-7. Archives of Internal Medicine. 
2006;166(10):1092–1097. https://doi.org/10.1001/archinte.166.10.1092 
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APPENDIX 9: The Brief Psychiatric Rating Scale (BPRS) 
 
 
Overall JE. Gorham DR. The brief psychiatric rating scale. Psychological reports. 1962 
10:799-812. 
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APPENDIX 10: Patient screening tool  
 
For Salvation Army Harbor Light facility staff: 
 
If during an intake interview, a new patient meets ALL of the following criteria (check 
off): 
 
 Male sex 
 
 At least 18 years of age 
 
 Admitted to Salvation Army Harbor Light 
 
 Dual diagnosis of substance abuse disorder and either: 
 
o Major depressive disorder 
 
o Bipolar disorder 
 
o Generalized anxiety disorder 
 
o Schizophrenia 
 
If a patient has evidence of a substance-induced psychiatric disorder, they are NOT 
ELIGIBLE. 
 
If the patient meets these above criteria, please make the following offer: 
“There is currently a research study being conducted here at the Salvation Army 
Harbor Light facility that is looking to determine if adherence to medications for 
mental health conditions has any connection to relapse in substance use. Would 
you be interested in speaking with someone regarding participating in this 
study?” 
 
If the patient expresses interest after this offer, please contact one of the study 
investigators. 
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APPENDIX 11: Consent to Participate in a Research Study Form 
 
DUQUESNE UNIVERSITY 
600 FORBES AVENUE      PITTSBURGH, PA 15282 
     
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
TITLE: Non-adherence to psychotropics and risk for substance use disorder relapse among 
patients with dual diagnosis 
 
INVESTIGATORS:   
 
Tyler Dunn 
Masters student  
Duquesne Univ Mylan School of Pharmacy 
 
Minha Choi 
Bachelors/Pharm.D. student 
Duquesne Univ Mylan School of Pharmacy 
 
Jordan R Covvey, PharmD, PhD, BCPS 
Assistant Professor 
Duquesne Univ Mylan School of Pharmacy 
412.396.2636 
Khalid M Kamal, MPharm, PhD 
Associate Professor 
Duquesne Univ Mylan School of Pharmacy 
412.396.1926 
Lauren Jonkman, PharmD, MPH, BCPS 
Assistant Professor 
Univ of Pittsburgh School of Pharmacy 
412.648.8563 
Vincent Giannetti, PhD 
Professor 
Duquesne Univ Mylan School of Pharmacy 
412.396.6379 
 
SOURCE OF SUPPORT: 
 
This study is being performed as partial fulfillment of the requirements for the Masters degree in 
Pharmacy Administration (Dunn) and a Bachelors degree in Pharmaceutical Sciences (Choi) at 
the Duquesne University Mylan School of Pharmacy. 
 
PURPOSE:  
 
You are being asked to participate in a research study that is evaluating whether medication 
adherence (taking your medication as directed) for depression, bipolar disorder, generalized 
anxiety or schizophrenia and substance use disorder has a connection to substance abuse 
relapse.  
 
To participate in the study, you must be male, at least 18 years of age and part of the residential 
program at the Salvation Army Harbor Light facility. You must also report a diagnosis of a 
substance use disorder and either major depressive disorder, bipolar disorder, generalized 
anxiety or schizophrenia. The study aims to determine if adherence to medications for these 
conditions is connected with lower rates of relapse in substance use. 
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PARTICIPANT PROCEDURES: 
 
To participate in this study, you will be asked (1) to provide permission to access to your Harbor 
Light record to collect information about you and your health and medication history, (2) to 
participate in an interview with one of our study investigators to answer questions about 
medication, substance use and your mental health, and (3) permission to contact you at one (1) 
and (2) months after the interview for follow-up questions regarding medication, substance use 
and your mental health. The in-person interview is expected to take approximately 30-45 minutes 
and the follow-up phone calls should take approximately 5-10 minutes each. Study investigators 
will take notes on paper during your interview and phone calls. These are the only requests that 
will be made of you.  
 
RISKS AND BENEFITS:  
 
For the interview and phone calls, you will be asked questions regarding your mental health 
history. If you experience any stress or become tired while talking with the study investigator, you 
will be allowed to stop and take a break. You do not have to answer questions that you do not 
want to answer. The study investigators will also view and collect more data from your Harbor 
Light record. However, at no point will you receive any physical or mental treatment within the 
study. You are only providing information to the study investigators.  
 
You are free to stop study participation at any time. There are minimal risks associated with this 
participation but no greater than those encountered in everyday life. There are no direct benefits 
to you, but the information from the study could help to provide better support and treatment to 
others with substance abuse in the future. 
 
COMPENSATION:   
 
Your time and participation in the study will be reimbursed in cash based on your level of 
participation. If you are enrolled in the study, you will receive $10.00 for completing your in-
person interview, and $10.00 for follow-up phone calls at 1-month and 2-months (a total of $30.00 
maximum per person). This payment will be provided as the study continues. Participation in the 
project will require no monetary cost to you.   
 
CONFIDENTIALITY:  
 
Your participation in this study and any personal information that you provide will be kept 
confidential at all times and to every extent possible.  
 
Your name will never appear in any data entry and will only be used to conduct interviews and 
follow-up.  Instead, you will be given a study number (Patient 1, 2, 3…) which will keep your 
identity anonymous in all recorded data. All written and electronic forms and study materials will 
be kept secure. After completion of the study, the information collected will be uploaded and 
stored on a secure computer until the data analysis is complete. Your response(s) will only 
appear in statistical data summaries. Any study materials with personal identifying information will 
be maintained for three years after the completion of the research and then destroyed. 
 
If while during the study or follow-up you express concerns that require clinical help (such as 
suicidality), study investigators will be required to inform facility personnel. 
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HIPAA AUTHORIZATION:  
 
You understand that by participating in this study, you are giving us permission to use your 
personal health information in your medical record and information that can identify you. The 
health information procedures in this study are HIPAA compliant. Any health protected 
information obtained will be stored by the researcher for six years after the completion of the 
study.  
 
RIGHT TO WITHDRAW: 
 
You are under no obligation to participate in this study and may stop participation at any time. 
Initial enrollment or any subsequent discontinuation from the study will in no way affect services 
provided or accessed within the Harbor Light Center. You are free to withdraw your consent to 
participate at any time by communicating your wish to your study investigator or any Harbor Light 
staff member. 
 
SUMMARY OF RESULTS: 
 
A summary of the results of this research will be supplied to you, at no cost, upon request. 
 
VOLUNTARY CONSENT: 
I have read the above statements and understand what is being requested of me. I also 
understand that my participation is voluntary and that I am free to withdraw my consent at any 
time, for any reason. On these terms, I certify that I am willing to participate in this research 
project. 
 
I understand that should I have any further questions about my participation in this study, I may 
call Dr Covvey at 412.396.2636, Dr Kamal at 412.396.1926 or Dr Giannetti at 412.396.6379. 
Should I have questions regarding protection of human subject issues, I may call Dr. David 
Delmonico, Chair of the Duquesne University Institutional Review Board, at 412.396.1886.   
 
 
________________________________________   __________________ 
Participant's Signature (Patient ID =                      )   Date 
 
 
 
________________________________________   __________________ 
Researcher's Signature       Date 
 
 
